

Common methods in mitochondrial research (Review)

YIYUAN YIN and HAITAO SHEN

Department of Emergency Medicine, Shengjing Hospital of China Medical University,
Shenyang, Liaoning 110004, P.R. China

Received May 10, 2022; Accepted August 9, 2022

DOI: 10.3892/ijmm.2022.5182

Abstract. Mitochondrial abnormalities are primarily seen in morphology, structure and function. They can cause damage to organs, including the heart, brain and muscle, by various mechanisms, such as oxidative stress, abnormal energy metabolism, or genetic mutations. Identifying and detecting pathophysiological alterations in mitochondria is the principal means of studying mitochondrial abnormalities. The present study reviewed methods in mitochondrial research and focused on three aspects: Mitochondrial extraction and purification, morphology and structure and function. In addition to classical methods, such as electron microscopy and mitochondrial membrane potential monitoring, newly developed methods, such as mitochondrial ultrastructural determination, mtDNA mutation assays, metabolomics and analyses of regulatory mechanisms, have also been utilized in recent years. These approaches enable the accurate detection of mitochondrial abnormalities and provide guidance for the diagnosis and treatment of related diseases.

Contents

1. Introduction
2. Extraction and purification of mitochondria
3. Determination of mitochondrial morphology and structure
4. Determination of mitochondrial function
5. Treatment of mitochondrial diseases
6. Summary and outlook

1. Introduction

Mitochondria are semi-autonomous organelles found in most eukaryotic cells with a bilayered structure consisting of an outer membrane, an intermembrane space and an inner membrane. They serve key roles in a variety of cellular processes, including cell metabolism, signal transduction and the regulation of cell death. Mitochondria have numerous biological functions, including the production of ATP for cellular energy, regulation of the dynamic balance of intracellular Ca^{2+} , production of reactive oxygen species (ROS), the release of cytochrome c and regulation of intracellular environmental homeostasis. As an important signaling hub in cells, the mitochondrion serves a key role in diseases such as aging and obesity. Mitochondrial biogenesis and mitochondrial homeostasis require the expression of nuclear genes and mitochondria-nuclear signaling pathways to be regulated (1). On the one hand, it depends on the regulatory pathways of nuclear gene transcription and anterograde signaling. Mitochondria, on the other hand, pass intracellular signaling molecules, such as Ca^{2+} , mitochondrial DNA (mtDNA), reactive oxygen species (ROS), adenosine triphosphate (ATP), coenzyme Q (CoQ) and nicotinamide adenine dinucleotide (NAD) and then present mitochondrial abnormalities and cellular metabolic change signals to the nucleus (retrograde signaling). This triggers the nucleus to activate important signaling pathways by mobilizing a series of nuclear transcription factors (2-5), mitochondrial transcription and mitochondrial biosynthesis. Among them, the activation of signaling pathways is closely related to inflammation and tumorigenesis (6). During cellular stress and virus infection, mtDNA and ROS are released from abnormal mitochondria and retrogradely presented to the nucleus as danger signals. The nucleus can promote the expression of PTEN-induced kinase 1 (PINK1) and then upregulate mitophagy to clear abnormal mitochondria and maintain a stable intracellular environment. When too many abnormal mitochondria cannot be completely removed, mtDNA can activate Toll-like receptor 9 (TLR9) and its downstream inflammatory pathways and lead to inflammation. Excessive ROS can cause DNA damage by oxidizing nucleic acid bases, which is closely related to tumorigenesis. Abnormalities in mitochondrial structure and function can lead to a variety of intracellular signaling cascades, oxidative stress and the initiation of programmed cell death, thereby contributing to the development and progression of nearly all diseases. Therefore, the detection of mitochondrial abnormalities is crucial and various mitochondrial assays (Fig. 1) developed

Correspondence to: Professor Haitao Shen, Department of Emergency Medicine, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping, Shenyang, Liaoning 110004, P.R. China
E-mail: shenht@sj-hospital.org

Key words: mitochondria, mitochondrial morphology, mitochondrial dysfunction, mitochondrial DNA, mitochondrial diseases

in the last century have contributed substantially to the differential diagnosis of mitochondrial diseases. The present study reviewed common experimental methods (Table I) in mitochondrial research. In particular, it discussed a wide range of imaging and detection techniques for i) extraction and purification, ii) analyses of morphology and structure and iii) analyses of function, with a focus on the clinical implications for disease detection and treatment.

2. Extraction and purification of mitochondria

A suitable method is needed to extract purified mitochondria from various tissues and cells (7). The basic extraction method mainly relies on differential centrifugation, while purification mainly depends on density gradient centrifugation. The specificity of tissue cells determines the details of the method (8-10).

Extraction of mitochondria. When extracting mitochondria, because the homogenization process can heat the sample locally, resulting in protein denaturation and aggregation, the equipment must be pre-cooled and the temperature kept low throughout the process (11). Tissue or cell homogenization is followed by continuous differential centrifugation. Unlysed cells, cell debris and nuclei are first removed by low-speed centrifugation ($600 \times g$ or $1,000 \times g$) (12-15). As mitochondria can remain in flaky precipitates generated by low-speed centrifugation, resuspending the pellet and centrifuging it again at low speed increases mitochondrial yield. The supernatant obtained by two low-speed centrifugation steps is collected for high-speed centrifugation ($3,500 \times g$ or $10,000 \times g$) (12-15), resulting in a coarse-lifted mitochondria precipitate (16). The purity of these crudely extracted mitochondria can meet some applications, including the analysis of the activity of known mitochondrial proteins, the detection of mitochondrial morphology and mitochondrial apoptosis; however, they often contain a certain amount of peroxisomes, endoplasmic reticulum and microsomes. Mitochondrial purity is low; thus, mitochondrial purification and reduction of membrane fouling are required when analyzing proteins present in multiple cells or determining the localization of a protein (17). Furthermore, although the mitochondrial extraction method is suitable for most tissues and cells, the extraction efficiency and quantity of mitochondria in different tissues and cells are significantly different. This is determined by the number of mitochondria in the tissue or cell and the energy consumption of muscles and liver; larger tissues contain more mitochondria, so these tissues and cells have higher mitochondrial extraction efficiency than other tissues, such as the lungs (18-20).

Purification of mitochondria. Purified mitochondria are the prerequisites for mitochondrial proteomics research. Density gradient centrifugation emerged in the 1950s and has become a common method for separating extracts owing to its ease of operation and low cost (21). For example, sucrose density gradient centrifugation suspends the cell or a homogeneous tissue slurry in a uniform suspension medium according to the density of each cell component and is separated by differential centrifugation (22-24). The buffered sucrose solution, the most commonly used suspension medium, is relatively close to the dispersion phase of the cytoplasm and can maintain the structure of various organelles and the activity of enzymes to a certain extent (25-28).

Sucrose density gradient centrifugation is a classic method for extracting mitochondria by separating cellular fractions of different densities (29). It involves three main processes: Tissue homogenization, fractionation and analysis (30-32). Homogenization refers to the disruption of cells or tissues in a homogenizer by adding sucrose at a low temperature to form a homogenate containing various organelles and other substances (33). Fractionation is the sequential settling of particles of different densities and sizes in the sample by centrifugation at different speeds. Analysis refers to the use of biochemical methods to identify the morphological function of the separated components; it is conducted using the Janus green live dyeing method, which is easy to operate and stable in performance. However, at high concentrations, sucrose has a high viscosity and high osmotic pressure, which can easily cause repeated shrinkage and mitochondrial expansion. Compared with sucrose, the price of commonly used density gradient media (including Percoll, Nycodenz and OptiPrep) is generally higher, but the morphology of the extracted mitochondria is generally complete. Percoll has a low diffusion constant, the gradient formed is very stable and it does not penetrate the biofilm; as such, it minimizes organelle rupture and is often used to isolate platelet mitochondria (12,34,35). Nycodenz is increasingly widely used owing to its high density, low viscosity and lack of effect on osmotic pressure (36-38). The yield of intact mitochondria is significantly higher in Nycodenz gradients containing sorbitol as an osmotic stabilizer instead of sucrose (37,38). As a dimer of Nycodenz, OptiPrep has the advantage of forming automatic gradients in a short period of time (39-42). Additionally, some researchers use streptavidin magnetic beads to separate *Arabidopsis* mitochondria. After the tissues are lysed, they are mixed with anti-mitochondrial outer membrane protein 22 (TOM22) magnetic beads and the mixed samples placed in the sorting column. Only mitochondria remain on the sorting column after washing, followed by elution, isolating the complete mitochondria in less than 30 min with a success rate, purity and integrity significantly higher than the density gradient centrifugation (43-47). Therefore, the magnetic bead method can be used to extract mitochondria in tissues with fewer mitochondria. As such, this approach will probably become increasingly common in mitochondrial extraction and purification (48-50). In conclusion, among the current mitochondrial extraction and purification methods, the magnetic bead method has the best effect on eliminating impurities such as microsomes and peroxisomes and the mitochondrial purity obtained by the differential centrifugation method is the lowest and the effect on eliminating these impurities is the worst.

3. Determination of mitochondrial morphology and structure

Mitochondria are organelles with a complex bi-membrane structure that regulate the entry and output of proteins, lipids, solutes and metabolite products and protect the cytoplasm from harmful mitochondrial products (51-53). Mitochondria can engulf abnormal mitochondria and remove excess harmful mitochondrial products to protect the body. This process is called mitophagy (54-56). Most mitochondria are spherical, rod-shaped, or tubular; however, mitochondrial morphology varies widely among tissues and cells depending on the energy




Figure 1. Commonly used research methods for mitochondria.

requirements of cells and the location of mitochondria within the cell (53,57). For example, mitochondria are spherical at synaptic terminals, whereas they appear as highly elongated rods in axons. In senescent and functionally impaired cells, mitochondrial morphology is significantly different from that in normal cells and they can be irregularly shaped (53,58,59). Therefore, morphological changes can be used in the initial assessment of mitochondrial function.

After over 50 years since its development, electron microscopy (EM) has become the central tool for observing organelles in eukaryotic cells and is the gold standard for observing mitochondrial structure (60). It can reveal mitochondrial swelling, rupture and other abnormalities of damaged mitochondria. However, it cannot clearly distinguish mitochondria from other membranous structures and is occasionally confusing. In the 1980s, atomic force microscopy, as an emerging observation method, could study the surface structure and properties of substances by detecting the extremely weak interatomic interaction between the surface of the sample to be tested and a miniature force-sensitive element. Due to the characteristics of resolution and real-time imaging, changes such as the formation of mitochondrial swelling can also be observed under liquid conditions but are significantly affected by the probe; thus, the application range is small (61-64).

The recently developed AiryScan microscope (Zeiss AG) can acquire images at high speed with high sensitivity to effectively observe the kinetic processes of mitochondrial fission, fusion and autophagy (65-67). In addition, both wide-field fluorescence microscopy and high-resolution confocal laser scanning microscopy can be used for imaging analyses of morphological changes in mitochondria with higher specificity

than that of EM, but the dynamic changes of the mitochondria cannot be observed (68-76).

In most cases, microscopy can be used to observe and analyze two-dimensional mitochondrial morphologies and quantities. However, although this method is suitable for analyzing adherent cells with flat morphology, it is not suitable for thicker cells (77-83). Three-dimensional confocal microscopy can be used to observe mitochondrial morphology by observing specifically labeled mitochondrial proteins at the 3D level (84-87). In addition, after labeling mitochondria with specific dyes, mitochondrial morphology can be visualized using a combination of immunofluorescent staining and computer images (58,88,89).

4. Determination of mitochondrial function

Determination of mitochondrial membrane potential. Mitochondrial membrane potential (MMP) refers to the negative potential difference between the two sides of the inner mitochondrial membrane. It is a sensitive indicator for evaluating mitochondrial function (90-93). It is closely associated with cellular homeostasis and is most commonly used to determine the metabolic state of mitochondria (93-98).

Fluorescent dye probes used for flow cytometry are now commonly used in MMP assays. For example, rhodamine 123, a specific stain developed in the 1980s, is widely used in flow cytometry and MMP assays. In normal cells, rhodamine 123 can selectively enter the mitochondrial matrix depending on MMP and can emit bright yellow-green fluorescence; when cells undergo apoptosis or necrosis, the mitochondrial membrane permeability transition pore (mPTP) is abnormally opened and

Table I. Summary of mitochondrial research methods.

Area of research	Methods	Scope of application	Advantages	Drawbacks
Extraction and purification of mitochondria	Differential centrifugation extraction	Tissues and cells	Detect mitochondrial morphological structure	Low mitochondrial purity
	Density gradient centrifugation	Sucrose	Low cost and wide application	Poor mitochondrial morphological integrity
	Purification (different media)	Peroll Nycodenz	Isolate platelet mitochondria Compared to sucrose, higher density and lower viscosity without affecting osmotic pressure	Higher cost compared to sucrose
Mitochondrial morphology			Automatic gradients can be formed in a short time	
	Magnetic bead method	Tissues and cells	Mitochondrial purity and integrity superior to other methods	Not yet widely used
	Electron microscope		Gold standard	Cannot clearly distinguish mitochondria from other membranous structures
	AiryScan microscope		Observable mitochondrial dynamics	Not yet widely used
	Atomic force microscope		Observation of mitochondrial swelling and mitochondrial dynamics	
		Thicker cells	For thicker cells	
Mitochondrial function	3D Confocal Microscopy	Tissues and cells	Intuitively reflect changes in MMP	High cytotoxicity
	Mitochondrial membrane potential		Low cytotoxicity for quantitative analysis of MMPs	Not yet widely used
	Rhodamine 123, JC-1		Extremely sensitive to detect minute changes in MMP	
	TMRM, TMRE		Monitoring dynamic changes of MMP	
	TRR-CY			
Mitochondrial oxygen consumption			FRET	
	Mitochondrial oxygen consumption	Tissues and cells	Low cost, detection of respiratory control rate	Poor specificity
Mitochondrial Ca^{2+} Detection			Comprehensive analysis of mitochondria by measuring oxygen consumption rate	Can be affected by chemicals such as phenol red
	Mitochondrial Ca^{2+} Detection		Suitable for experiments with low sensitivity, unable to distinguish mitochondrial Ca^{2+} from total Ca^{2+}	Poor specificity

Table I. Continued.

Area of research	Methods	Scope of application	Advantages	Drawbacks
Mitochondrial function	Calcium-Rhodamine 123	Tissues and cells	High specificity, suitable for the detection of mitochondrial Ca^{2+} in various living cells	Inability to distinguish between different cellular sources of Ca^{2+}
	Fluo-3		Distinguish mitochondrial Ca^{2+} from Ca^{2+} in other intracellular organelles	
	Fully automatic patch clamp	Suspension cells	Can be used for detection of suspension cells	Small scope of application
	Calcein-AM	Tissues and cells	Strong specificity, can reflect the opening degree of mPTP in real time	Easy to be quenched, timely observation is required
	High pressure liquid chromatography	Tissues and cells	Can detect differences in cellular energy substances in different states	Requires a larger sample size
	Enzymatic analysis		It is greatly affected by the absorbance of the tested sample	Susceptible to redox reactions
	Fluorescence analysis		The amount of luminescence is proportional to ATP	Easy to quench
	Mito-Rh		Can specifically recognize ATP in mitochondria	
	Spectrophotometry	Tissues and cells	Wide range of applications, but less accurate	Vulnerable to external biochemical interference
	NIR spectroscopy non-invasive measurements		Less affected by the outside world, high accuracy	Requires a very large sample size
ROS	Chemical reaction selective electrode method	Tissues and cells	High sensitivity, cheap and easy to operate, but poor specificity and unstable results	Poor specificity and unstable results
	Spectrophotometry		High sensitivity and specificity, but cannot perform localization analysis of oxygen free radicals	Unable to perform localization analysis of oxygen free radicals
	Reagent test kit		Strong specificity, easy operation, low background, large detection range, easy quenching	Easy to quench

Table I. Continued.

Area of research	Methods	Scope of application	Advantages	Drawbacks
Mitochondrial DNA	Electron spin resonance		The most direct and effective, expensive and complicated operation	Expensive and complicated to operate
	PCR	Tissues and cells	Detectable mtDNA deletions	The presence of mtDNA heterogeneity in the primer binding region
	FISH		Visually detectable under a fluorescence microscope	Poor specificity and insufficient hybridization
	Sequencing		Gold standard for detecting heterogeneity	Limited to small scale projects
	Probe method		Detect mtDNA dynamic changes	Need real-time observation
TMRM, tetramethyl rhodamine methyl ester; TMRE, tetramethyl rhodamine ethyl ester; FRET, fluorescence resonance energy transfer; FISH, fluorescence <i>in situ</i> hybridization; MMP, mitochondrial membrane potential; mtDNA, mitochondrial DNA.				

MMP is unbalanced. Rhodamine 123 is released from mitochondria, resulting in a significant decrease in the yellow-green fluorescence intensity in mitochondria, which reflects the changes in MMP (50,99-102). 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) has higher sensitivity than that of rhodamine 123. At low MMP levels, JC-1 exists as a monomer and produces green fluorescence; at high MMP levels, JC-1 aggregates in the mitochondrial matrix and forms polymeric JC-1. This can be used for qualitative and quantitative analyses of MMP by fluorescence microscopy or flow cytometry (50,96,101,103-108). Tetramethyl rhodamine methyl ester (TMRM) and tetramethyl rhodamine ethyl ester (TMRE), like JC-1, are specific dyes that have recently become common tools for measuring MMP (109-112). TMRM can be excited at 488 nm, showing red-orange fluorescence and its fluorescence intensity has a linear relationship with MMP. Compared to rhodamine 123 and JC-1, these two dyes are very soluble, have short loading times (15-20 min) and have extremely low cytotoxicity, requiring micromolar inhibition of mitochondrial function. With staining concentrations in the range of 0.5-30 nM (the concentration of JC-1 needs to be >0.1 μ M), the accumulation in mitochondria is limited to the change of membrane potential and the sensitivity is extremely high; this is markedly suitable for quantitative analysis of mitochondrial membrane potential and quantitative flow cytometry (113-118). However, in quantitative flow cytometry studies, the data must be corrected for the signal of MitoTracker Green FM, a dye that is not dependent on mitochondrial membrane potential. It is worth noting that the above fluorescent probes for measuring MMP are applicable to most tissues and cells, including plant cells and bacteria.

Fluorescence resonance energy transfer (FRET) is a non-radiative energy transition that transfers energy from the excited state of the donor to the excited state of the acceptor through intermolecular electric dipole interactions (119,120). This process does not involve photons, so it is non-radiative. This analytical method has the advantages of rapidity, sensitivity and simplicity. Fluorescence resonance energy transfer molecular pairs (FRET Pairs) have been designed and synthesized to monitor MMPs (121). The FRET donor molecule (FixD) is constructed by attaching a benzyl chloride group to a fluorophore with green fluorescence emission. FixD can be attached to and fixed in mitochondria by sulfhydryl groups of mitochondrial proteins. The FRET acceptor (LA) is a mitochondrial membrane potential-dependent probe with green absorption and deep red fluorescence emission. When MMP is at a normal level, both FixD and LA target mitochondria. When FixD has an excitation wavelength of 405 nm, FRET occurs between FixD and LA, allowing green fluorescence to be detected but not deep red LA fluorescence emissions. When MMP is gradually reduced, LA will gradually fall off from mitochondria. While FixD is still fixed in mitochondria, the distance between the molecules gradually blocks the occurrence of FRET between FixD and LA molecules, allowing deep red fluorescence emission to be detected gradually. The decrease and the gradual increase of green fluorescence emission can be used to monitor the dynamic changes of MMPs (122), providing new ideas for the development of novel MMP fluorescent probes and real-time *in situ* studies of MMPs in living organisms, tissues and cells (123,124).

MMP varies greatly among sites on the mitochondrial membrane; therefore, accurate measurement of MMP requires further study (125). In recent years, low concentrations of a hemicyanine derivative (TPP-CY) have been used to monitor trace changes in MMP at the subcellular level during apoptosis with very high sensitivity (125). This approach is a potentially useful tool for evaluating cell health.

Determination of mitochondrial oxygen consumption. Among organelles, mitochondria consume the most oxygen in cells and this oxygen consumption often reflects mitochondrial function (126-128). In the heart, mitochondrial oxygen consumption can be measured to determine cardiac mitochondrial function, providing an indicator of cardiac function (129-131). In children, mitochondrial dysfunction causes mitochondrial heart disease with hypertrophic myocardial infarction as the primary symptom; however, the exact mechanism and etiology remain to be investigated (129,132).

Oxygen electrode polarography is a common method for determining mitochondrial oxygen consumption and refers to the incubation of mitochondria in an oxygen-consuming medium in a magnetically stirred incubator at 30°C. Briefly, rotenone is used to inhibit complex I in the electron transport chain, followed by the addition of succinate to measure mitochondrial state IV respiration (non-phosphorylating respiration). State III respiration is measured by incubating mitochondria in the presence of succinate and adenosine diphosphate. The respiratory control ratio (RCR) is the ratio of the state III respiration rate to state IV respiration rate, with a normal value of 3-10 (133-135). A low RCR indicates impaired mitochondrial ATP synthesis and mitochondrial dysfunction and a high RCR indicates vigorous cellular activity and accelerated metabolism (127,136,137).

In addition, the hippocampal analyzer can measure the changes in oxygen and pH levels through sensors and then automatically calculate the rate and detect the cellular oxygen consumption rate (OCR) and extracellular phosphorylation rate (ECAR) in real time to characterize the metabolic status of cells. Where OCR is caused by mitochondrial electron transfer, ECAR is derived from lactic acid fermentation (glycolytic acidification) and carbon dioxide produced by mitochondria (mitochondrial acidification) (138-140).

OCR is used to study mitochondrial oxidative phosphorylation function, with pMoles/min as the readout type (141). Generally, basal respiration in a normal state is measured first and then oligomycin is added to inhibit ATP synthase. This is a significant decrease in OCR, leaving only proton leakage (142). The oxygen consumption rate is caused by proton leakage and the reduced section is the oxygen consumption rate (ATP production) of oxidative phosphorylation. With the addition of the uncoupling agent FCCP, electron transport loses the constraints of the proton gradient and proceeds at a maximum rate (143). Therefore, the OCR increases sharply, reaching the maximum oxygen consumption (maximal respiration); the difference between this value and the basal respiration is termed the spare respiratory capacity. Finally, adding an electron transport inhibitor, such as antimycin A, completely inhibits electron transport and reduces the oxygen consumption rate to a minimum (144).

ECAR is often used to study metabolic conditions such as glycolysis, with mpH/min as the readout type (139,140,142). The basal value before adding glucose is non-catalytic acid production, such as mitochondrial acidification caused by carbon dioxide produced by mitochondrial respiration. Glucose is then added and the elevated value represents glycolysis. After the addition of oligomycin, the production of acid increases because oxidative phosphorylation is inhibited and the cells are forced to use lactic acid fermentation for energy. The value at this time is called glycolytic capacity and the difference from glycolysis is termed glycolytic reserve (140,142,143). Last added is 2-deoxyglucose, a competitive hexokinase inhibitor that can block glycolysis, so the curve should return to the basic value following its addition (144-146).

However, the direct measurement of glycolysis by ECAR is somewhat biased since the addition of glucose enhances glycolysis and oxidative phosphorylation. This will lead to increased mitochondrial acidification, causing the calculated amount of glycolysis to be high (147-149).

It is worth noting that during the measurement process of the hippocampal analyzer, the interference of phenol red should be avoided because it causes errors in the measurement results (141,150,151), but the specific reasons remain to be elucidated. In conclusion, the hippocampal analyzer can monitor OCR and ECAR to obtain multiple other parameters in a single analysis, including basal respiration, ATP-related respiration, maximal respiration, spare respiratory capacity and non-mitochondrial oxygen consumption, all of which can provide information on the mechanism of mitochondrial dysfunction (152,153).

Determination of mitochondrial Ca^{2+} . Intracellular Ca^{2+} is primarily stored in organelles, such as the mitochondria and endoplasmic reticulum, and serves an important role in biological processes such as signal transduction, blood coagulation, transmembrane ion transport and cell division (154-156). Mitochondrial Ca^{2+} is a central regulator of oxidative phosphorylation and serves a key role in the control of ATP synthesis (157). A Ca^{2+} imbalance can cause abnormal mitochondrial function and even cell damage and death, leading to pathological changes and affecting organismal health (158,159). The accumulation of mitochondrial Ca^{2+} promotes ATP synthesis in mitochondria; conversely, decreased mitochondrial Ca^{2+} leads to a decrease in mitochondrial ATP. Impaired ATP synthesis further leads to a Ca^{2+} imbalance (157,159), which in turn leads to endocrine dysfunction and numerous diseases, such as mitochondrial diabetes mellitus (160-165).

Methods for the determination of mitochondrial Ca^{2+} include precipitation, electrochemical analysis, EDTA chelation titration, flame photometry and atomic absorption spectroscopy, among which electrochemical analysis is the most convenient (87,88,156,166-168). First developed in the 19th century, the electrochemical analysis applies electrochemical principles and techniques to a class of analytical methods that take advantage of the electrochemical properties of chemical cells in solution and their changes. It can be used for the detection of both organic and inorganic substances and is simple in operation. It can be both qualitative and quantitative, but is susceptible to interference by sodium,

potassium, phosphate and sulfate. It is suitable for real-time detection and experiments with low optical sensitivity requirements (132,169). In addition, FRET can also detect Ca^{2+} ; cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) are the most widely used FRET pairs in protein-protein interaction studies. The emission spectrum of CFP is similar to that of YFP. The absorption spectra of CFP overlap and when the distance between the two proteins is in the range of 5-10 nm, the fluorescence emitted by CFP can be absorbed by YFP and YFP is excited to emit yellow fluorescence. Whether the two proteins interact was determined by measuring the loss of CFP fluorescence intensity. The closer the two proteins are, the more fluorescence emitted by CFP is received by YFP and the less fluorescence is received by the detector. CFP and YFP are fused to calmodulin and calmodulin-binding peptide, respectively and expressed in the same cell (170-175). When the intracellular Ca^{2+} concentration is high, the combination of calmodulin and the calmodulin-binding peptide can induce FRET and the receptor protein YFP emits yellow fluorescence, so the cells appear yellow. When the intracellular Ca^{2+} concentration is low, FRET hardly occurs, so CFP is excited and emits green fluorescence during detection and the cells appear green (170,171,175). FRET can detect intracellular Ca^{2+} , but cannot specifically detect mitochondrial Ca^{2+} . A number of fluorescent probes have recently been used for the measurement of Ca^{2+} levels, including Quin-2AM, fluo-3AM, indo-1AM, Rhod-2, Fluo-4, Mag-fluo-4 and calcium-rhodamine 123 (rhodamine 123) (158,176-178). Quin-2AM, fluo-3AM, indo-1AM, Fluo-4 are cytosolic Ca^{2+} indicators. Mag-fluo-4 is an ER Ca^{2+} indicator. The rhodamine 123 complex assay is suitable for the determination of mitochondrial Ca^{2+} concentrations in various living cells owing to its simple operation and stable performance. It can be quantified by fluorescence spectrophotometry to detect aggregation in mitochondria and thereby to measure the Ca^{2+} content (179-184). At present, Fluo-3 is a widely used typical single-wavelength fluorescent indicator with an excitation wavelength in the visible light range (185,186). The maximum absorption peak and maximum emission wavelength are located at 506 and 526 nm, respectively. The fluorescence intensity of Fluo-3 combined with Ca^{2+} is ~40 times higher than that of free cells, thus avoiding the fluorescence interference of the cells themselves (185,187). As a long-wavelength indicator, Fluo-3 can be used in confocal laser imaging studies that can analyze the distribution of Ca^{2+} in individual intact living cells and distinguish mitochondrial Ca^{2+} from Ca^{2+} in other organelles within the cell; this method is suitable for mitochondrial Ca^{2+} in various living cells and is easy to operate, stable in performance and highly specific (155,187). However, the current mitochondrial Ca^{2+} fluorescent probes cannot distinguish mitochondrial Ca^{2+} from different cells.

Detection of mitochondrial permeability transition pores. mPTP is a class of protein complexes between the inner and outer mitochondrial membranes that permit the passage of substances with a molecular weight of <1.5 kDa and serve as the structural basis for transitions in mitochondrial permeability (188-191). Additionally, mPTP is very sensitive to changes in intracellular and extracellular ion concentrations and serves an important role in signal transduction systems.

It is currently hypothesized that the abnormal opening of mPTP is closely associated with abnormal changes in Ca^{2+} concentrations, oxidative stress and mitochondrial DNA (mtDNA) mutations (154,188,189,192,193). By contrast, MMP and mitochondrial Ca^{2+} concentrations are the principal drivers of mPTP opening, resulting in the release of cytochrome c and other substances associated with cell death into the cytosol (191,192,194-197). This leads to mitochondrial swelling and reduced mitochondrial respiratory chain activity, which can cause various diseases, such as neurodegenerative diseases and cancers (190,198-200). Furthermore, studies have shown that PINK1 can inhibit mPTP opening by downregulating intracellular ROS levels, suggesting that mitochondrial autophagy serves a regulatory role in mPTP opening (191-193). Various methods have been developed for detecting mPTP, such as the patch-clamp, spectrophotometric and active substance labeling methods. The patch-clamp method is the earliest, originating in 1976 and can reflect ion channel activity by recording ion channel currents to evaluate mitochondrial function (188,189,201). As the magnification of AFM is as high as 1 billion times, the opening of mPTP can be directly observed, which can serve a guiding role in the abnormal opening of mPTP (202-205). Fully automated patch-clamp techniques have recently emerged; these are simple in operation and have greatly improved efficiency but are only applicable to the detection of cells in suspension. Compared to the active substance labeling and patch-clamp methods, spectrophotometry is simpler and more commonly used.

The calcein-cobalt fluorescent probe technique is an emerging technique for the detection of mPTP and is simple in operation and highly sensitive (Fig. 2). Calcein-AM (190,194, 198,206,207), in which the acetylmethoxy methyl ester (AM) group enhances the hydrophobicity of the stain for easy penetration of the living cell membrane, is used to fluorescently label living cells. Next, calcein-AM is cleaved by intracellular esterases to yield highly fluorescent and polar calcein (208-210). When cells are incubated with calcein and Co^{2+} , both enter the cytoplasm; however, calcein is further captured by mitochondria (211,212). Calcein that accumulates in the mitochondria exhibits fluorescent staining, whereas calcein remaining in the cytoplasm or released from the mitochondria into the cytoplasm is rapidly quenched by Co^{2+} (213-219). Under normal physiological conditions, mPTP opens transiently and calcein that enters the cytoplasm from the mitochondria is rapidly quenched. In pathological states, such as calcium overload and oxidative stress, mPTP can appear to be continuously open and Co^{2+} in the cytoplasm can enter the mitochondria to quench the calcein fluorescence, resulting in a gradual decrease in fluorescence intensity in the mitochondria, thus indicating the degree of mPTP opening (195,196,220-222).

Determination of mitochondrial ATP. ATP is often considered the primary energy currency of cells and is primarily derived from the mitochondria (137,223-228). It serves major roles in material transport, energy conversion and information transfer. Mitochondria are sensitive to external environmental stimuli, such as hypoxia, oxidative stress, toxic substances and high glucose. Once mitochondria are damaged, ATP production decreases and free radical production increases, which




Figure 2. The working mechanism of calcein-AM probe when mPTP is abnormally opened: ① Calcein-AM and Co^{2+} enter the cell, ② Calcein-AM is then cleaved by intracellular esterase, ③ Calcein is quenched by Co^{2+} and ④ Co^{2+} quenches calcein through abnormally open mPTP. mPTP, mitochondrial membrane permeability transition pore.

affects a number of cellular processes and contributes to the development of a number of diseases, such as Parkinson's disease, cancer, cardiovascular disease and endocrine dysfunction (224-227). Therefore, ATP levels are a key indicator of the status of cellular energy metabolism and mitochondrial function.

Analyzing ATP levels requires freshly extracted mitochondria, as mitochondria must remain intact and in a coupled state (229). Several techniques are available to measure mitochondrial ATP levels, including chromatography, electrophoresis, high-performance liquid chromatography (HPLC) and enzymatic analysis (225,227,229-232). Chromatography and electrophoresis are chemical methods that were developed in the 18 and 19th centuries and have gradually improved. Classic liquid chromatography uses a large-diameter glass tube column and a difference in liquid levels at room temperature and atmospheric pressure to force the mobile phase (231,232). However, this technique has low column efficiency and is very time-consuming (often requiring several hours). HPLC was developed based on classic liquid chromatography following the introduction of gas chromatography theory in the late 1960s. The differences between HPLC and classic liquid chromatography include a faster analysis speed, smaller and more uniform particles as packing material and high column efficiency of the small particles. However, this causes high resistance and requires high pressure to force the mobile phase; therefore, this technique is also known as high-speed liquid chromatography (233-235). HPLC can be used to determine differences in cellular energy substances in different states, is easy to operate and has high sensitivity (233-236). The enzymatic method is based on spectrophotometry, where ADP production is assessed by measuring the absorbance of NAD^+ in phosphoenolpyruvate (237-240). Fluorescence analysis techniques have been improved in recent years and are commonly used to determine mitochondrial ATP synthesis activity (241-244). For example,

in the luciferin-luciferase luminescence method, luciferin is rapidly oxidized under the action of luciferase, producing green fluorescence and the amount of luminescence is linearly correlated with the level of ATP (245,246). This is a fast and accurate method; however, fluorescein is an amphiphilic molecule whose carboxyl group is charged at physiological pH and thus does not easily cross the cell membrane (244-246). A novel synthetic fluorescent probe called Mito-Rh can specifically identify ATP in mitochondria with high sensitivity and a detection range of 0.1-10 mM. In another method, the level of ATP can be determined directly by measuring the amount of inorganic phosphate based on the principle that ATP gives rise to ADP and inorganic phosphate (225). In addition, FRET can also be used to detect the level of ATP synthesis after labeling the ATP synthase subunit. When CFP and YFP are labeled on ATP synthase subunits, when the ATP synthase activity is enhanced, the interaction between the subunits is enhanced, the shortened distance between the subunits brings CFP and YFP closer to each other and FRET occurs and CFP excites YFP to emit yellow fluorescence. The lower the green fluorescence intensity received by the detector, the higher the ATP synthase activity and the higher the ATP level. When ATP synthase activity is low, the interaction between subunits is weakened, FRET hardly occurs and CFP is excited at this time and the cell emits green light.

In addition, a multi-color ATP indicator has appeared in recent years. Different from the previous indicators that can only specifically detect intracellular ATP, the multi-color ATP indicator is based on a single fluorescent protein indicator with red, green and blue colors (247-249). Alternatively, it can simultaneously detect ATP in different organelles in the same cell and simultaneously detect ATP dynamics in the mitochondria of mammalian, plant and even worm cells and will have an assured role in promoting energy metabolism research in the future (225,226).

Detection of mitochondrial respiratory chain complexes. The mitochondrial respiratory chain, with functions in energy production, the regulation of cell death and calcium metabolism (183,250-253), is located on the inner mitochondrial membrane and consists of five complexes. Mitochondrial respiratory chain complex I (NADH oxidase) and mitochondrial respiratory chain complex II (succinate dehydrogenase) are the major elements for electrons entering the mitochondrial electron transport chain (ETC). Complex I oxidizes NADH and transfers electrons to coenzyme Q (254-257). Complex II transfers electrons from succinate to coenzyme Q, a process that does not involve proton transport (258-260). Mitochondrial respiratory chain complex III (cytochrome c reductase) is an essential protein for mitochondrial oxidative phosphorylation, the gatekeeper of the mitochondrial respiratory chain and a major source of third reactive oxygen species. Complex III transfers electrons from coenzyme Q to cytochrome c while using the released energy to pump protons into the intermembrane space. The mitochondrial respiratory chain complex IV (cytochrome c oxidase) is the terminal electron acceptor of the mitochondrial electron transport chain. Complex IV transfers electrons from cytochrome c to oxygen, half the number of protons is synthesized into water and the other half is pumped into the intermembrane space. Mitochondrial respiratory chain complex V and the above four complexes complete oxidative phosphorylation to generate ATP, which is called ATP synthase, also known as F1F0-ATPase (254,260-265). The energy released by complex V through the electron transport chain during respiration or photosynthesis is first converted into a transmembrane proton (H^+) gradient and the proton then flows along the proton gradient and passes through ATP synthase to enable ADP+Pi to synthesize ATP (266-269). It is also hypothesized that abnormalities in mitochondrial complexes are closely associated with mitochondrial encephalopathy, mitochondrial liver disease and mitochondrial nephropathy (265). It should be noted that the mitochondrial respiratory chain complex is closely related to the occurrence of tumors (251,270-272). Therefore, mitochondrial complex inhibitors may be used as a new treatment for tumors (252,253,260,273). Therefore, the accurate detection of mitochondrial complexes is essential and spectrophotometric assays remain the first-line technique for detecting the activity of mitochondrial respiratory chain complexes I-V (266,274,275).

Samples are generally selected from purified mitochondria and 4-40 μ g of mitochondrial protein is required per respiratory chain complex assay (257,269,276-279). To compare the activity of mitochondrial respiratory chain complexes in different cells or tissues, the activity of citrate synthase in the Krebs cycle is measured simultaneously as a control and the reaction system is carried out at 30°C in a volume of 200 μ l or 1 ml. The activity of complexes I and V is directly proportional to, and can be determined by measuring, the oxidation rate of NADH, which is measured as the decrease in absorbance at 340 nm (280). In the oxidation of succinate catalyzed by complex II, 2,6-dichlorophenolindophenol (DCPIP) is used as a dye and absorbance at 600 nm decreases as DCPIP decreases (259,281,282), which is used to measure the activity of complex II (283-287). The activity of complexes III and IV can be determined by measuring cytochrome activity

(absorbance at 550 nm) (268,288-294). However, the spectrophotometric method is susceptible to external biochemical interference that can lead to changes in enzyme kinetics (chemicals in the liquid or gas phase react with the sample resulting in a change in the absorbance of the sample), which can have serious effects on the sensitivity and accuracy of the assay (255,258,280,295-298). In addition, western blotting can directly reflect the expression level of respiratory chain complexes I-V in the band by using the specific antibody reaction of the complex, which has been widely used in experiments related to mitochondrial research (274,296,297). However, the protein expression level and protein activity are occasionally not correlated and spectrophotometry is still the preferred method for detecting mitochondrial respiratory chain complexes. In recent years, great progress has been made in the non-invasive measurement of mitochondrial complexes using near-infrared spectroscopy. This method is similar to spectrophotometry in principle but is less affected by the external environment (265-268). The fundamental reason why near-infrared light can achieve non-invasive optical measurement is that in the near-infrared light region of 600-900 nm, biological tissue is relatively transparent because the absorption of water and hemoglobin in this wavelength region is very small. As an 'optical window', some studies have used it to detect the activity of complex IV to judge the severity of depression. Myoglobin is essential for oxygen metabolism in muscle tissue, including a group of blood cells similar to hemoglobin. The most important of which is complex IV, which has been used to detect the activity of complex IV to judge the severity of depression (299,300). However, due to the large amount of samples required for near-infrared spectroscopy and different instrument models, it has severe limitations and has not been widely used (183,250-253).

Mitochondrial respiratory chain function can also be determined by RCR, which reflects both mitochondrial integrity and mitochondrial oxidative respiratory chain function (256,265,267,301).

Measurement of ROS. As the central organelle for cellular oxidative phosphorylation, mitochondria are the principal site of ROS production (3,302-305). Under physiological conditions, the intracellular antioxidant defense system is in equilibrium with oxygen radicals. The levels of intracellular ROS, including superoxide radicals, hydrogen peroxide and its downstream products (peroxides and hydroxyl radicals), are maintained at low physiological ranges. Under pathological conditions, the balance between the intracellular antioxidant system and oxygen radicals is disrupted. When intracellular ROS levels are too high, mitochondrial structure and function are impaired and cytochrome c is released through mPTP, resulting in damage to mitochondrial enzymes, lipids and nucleic acids as well as oxidative stress (303,306-310). ROS can also attack mitochondrial DNA (mtDNA) to produce oxidative damage, resulting in reduced mitochondrial ATP synthesis and MMP damage. Therefore, the functional status of mitochondria can be determined by measuring ROS levels (311-313).

Common methods for detecting ROS include the chemical reaction method, selective electrode method, spectrophotometry and direct detection by kits. ROS shows high reactivity and

can react with different compounds to produce various products, which can be analyzed quantitatively or qualitatively. The chemical reaction method is characterized by high sensitivity, low cost and simple operation; however, it has poor specificity and measurement results are easily affected by some redox reactions or enzyme-catalyzed reactions. Tetranitromethane, nitroterrazolium blue chloride (NBT), cytochrome c, epinephrine and reduced coenzyme I are commonly used for spectrophotometric methods; these react with superoxide anion radicals to produce ferrous cytochromes with a specific absorbance (detectable at a wavelength of 550 nm), which can be used to directly measure ROS levels (307,314-317). The NBT assay is highly sensitive and is commonly used for the histochemical localization of oxygen radicals; however, it is difficult to measure dynamic changes in oxygen radicals in cells or aqueous systems. Cytochrome c has oxidative activity and can be used to detect the production of oxygen radicals. However, cytochrome c is easily reduced by other reducing agents and is therefore limited for the accurate localization of oxygen radicals. In the last decade, a number of ROS kits have been developed to detect intracellular or mitochondrial ROS (mtROS) levels directly. Intracellular ROS are usually measured using the fluorescent probe DCHF-DA, which is non-fluorescent and can freely cross the cell membrane. After DCHF-DA enters cells, it is hydrolyzed by intracellular esterases to generate DCHF, which cannot enter or exit the cell membrane, thus allowing the probe to easily label the cell. In the presence of ROS, DCHF is oxidized to produce the fluorescent substance DCF, whose fluorescence intensity is directly proportional to intracellular ROS levels. mtROS is usually measured using the fluorescent probe MitoSOX, which is highly specific to mitochondrial ROS and is characterized by simple operation, low background signals, wide linear range and high detection efficiency; however, it requires the immediate imaging of assay results and protection from light to prevent fluorescence quenching. Prior to the widespread use of kits, ROS levels were indirectly measured by detecting products of oxidative damage. Levels of malondialdehyde (MDA) reflect the degree of lipid peroxidation in the body and can be measured using the thiobarbituric acid (TBA) chemical colorimetric method. Condensation under acidic conditions generates the MDA-TBA complex, a red product with a maximum absorption peak at 535 nm, which can be used to indirectly determine the MDA content by spectrophotometry, indicating ROS levels. However, this technique has poor sensitivity and is prone to contamination. Fluorescent protein-based ROS detection methods are designed by combining fluorescent proteins and prokaryotic redox-sensitive proteins (318,319). The recombinant proteins are introduced into cells via plasmids or adenoviruses and target organelles to detect intracellular redox status (320,321). Redox-dependent fluorescence spectral changes of recombinant proteins are achieved through structural changes of disulfide bonds and part of the backbone under oxidative conditions (319,321).

Electron spin resonance (ESR) technology has emerged in recent years. Also known as electron paramagnetic resonance (EPR), its principle is similar to nuclear magnetic resonance (322-325). The sample is controlled in a fixed frequency microwave and the applied magnetic field is then changed so that the electron energy level difference is the same as the

microwave energy (326,327). Unpaired electrons can move between the two energy levels and the net absorption energy of the microwave can be measured to obtain the ESR spectrum. Due to the high reactivity and short lifespan of ROS, the ESR signal is not easy to detect directly. The combination of ESR and spin traps can make up for this defect. The spin-electron trapping agent reacts with free radicals to generate relatively stable free radical addition products that are easily detected by ESR, which is then determined by ESR technology. This powerful and reliable technique can unambiguously measure the presence of free radicals in biological samples. ROS is the most direct and effective method for detecting free radicals and is widely used in physics, chemistry and biomedicine (328-331).

Detection of mtDNA. Human mitochondria carry a small circular double-stranded genome of 16569 bp known as mtDNA, which encodes mitochondrial 16S and 12S ribosomal RNA, 22 mitochondrial tRNA molecules and 13 respiratory chain proteins. Each organism contains only one type of mtDNA and mutations such as the conversion, inversion, insertion, or deletion of one or several bases of mtDNA, resulting in more than one type of mtDNA within an individual, are referred to as mtDNA heterogeneity (332-335). Owing to the lack of protective histones and effective DNA repair systems, the mutation frequency of mtDNA is ~10 times higher than that of nuclear DNA (336-339). Moreover, mutated mtDNA gradually accumulates and can cause irreversible damage to the nervous, cardiovascular, respiratory and reproductive systems after reaching a certain threshold (60-80%). In addition to these diseases, studies have also shown that mtDNA mutations are closely associated with the development of infertility (308,339-342). mtDNA dysfunction can be both quantitative (e.g., mtDNA copy number variation and deletions) and qualitative (e.g., strand breaks, point mutations and oxidative damage) (343-345).

mtDNA can be released from the cell as circulating free mitochondrial DNA (CCF-mtDNA) via extracellular vesicles (EVs) (346,347). CCF-mtDNA can serve as a damage-associated molecular pattern leading to the activation of inflammatory pathways, a process closely associated with TLR9. Numerous reports have shown that elevated levels of CCF-mtDNA are associated with various TLR9-dependent pathologies, such as rheumatoid arthritis, atherosclerosis, hypertension, acute liver injury and nonalcoholic steatohepatitis (48,348).

mtDNA damage can be detected using PCR, fluorescence *in situ* hybridization (FISH), DNA sequencing technology and the probe method, among others. The principle of DNA sequencing is to use DNA polymerase to extend the primers bound to the template of the undetermined sequence until a chain-terminating nucleotide is incorporated. Termination of replication and detection with isotopic labeling is the gold standard for detecting heterogeneity, but speed is limited when working on large-scale projects. The speed of large-scale projects was not guaranteed until the advent of high-throughput sequencing. PCR, as a molecular biology technology that emerged in the 1980s, is a method for enzymatically synthesizing and amplifying specific nucleic acid fragments *in vitro* based on the semi-conservative replication mechanism of DNA. This can purposefully amplify target regions and

is especially suitable for enriching small-scale genomes such as mtDNA (349-353). However, mtDNA is present in primer-binding regions, but accuracy is not sufficient due to heterogeneity. Over time, reverse transcription-quantitative (RT-q) PCR is able to monitor the number of amplified DNA molecules in real time, facilitating the determination of mtDNA in individual cells, along with the copy number and other impairments (deletions) (350-352). As a contemporaneous product of PCR, FISH is also a classic specific detection method. It uses fluorescently labeled specific nucleic acid probes to hybridize with corresponding target DNA or RNA molecules in cells. Fluorescent signaling with relatively poor specificity and insufficient hybridization compared to PCR is not the method of choice for the detection of mtDNA (149,354-362). Moreover, after the mitochondria are separated from cells or tissues, the DNA in the remaining material is extracted (kits can be used) and the DNA of the sample can be sequenced. qPCR or chromatin immunoprecipitation (ChIP) experimental methods can be used to detect the level of CCF-mtDNA, among which ChIP is often used to verify the binding of mtDNA to downstream signaling pathways, such as TLR9 inflammatory pathway or cGAS signaling pathway (335,363-371). As a DNA sensor in the cytoplasm, cGAS can recognize CCF-mtDNA and then catalyze the formation of the second messenger cGAMP (2'3'-cGAMP) to activate the interferon-stimulated gene-dependent signaling pathway. In addition, CCF-mtDNA containing unmethylated DNA (CpG DNA) fragments can be recognized by TLR9, causing TLR9 dimerization and activation of MyD88-mediated inflammatory pathway.

Unrepaired depurinated/depyrimidinated sites (AP sites) in mtDNA lead to the misbinding of nucleotides, which can have serious downstream effects (372-374). Therefore, the rapid and accurate quantification of AP sites in mtDNA is crucial for the real-time assessment of mtDNA oxidative damage. Researchers have used a specific fluorescent probe (BTBM-CN2) for the real-time detection of mtDNA (375-378). At ~20 sec after contact with AP sites, red fluorescence is detectable at 598 nm and after ~100 sec, green fluorescence is detectable at 480 nm. More AP sites result in green fluorescence with greater intensity and duration and the degree of mtDNA damage can be quantified based on the time of appearance and intensity of fluorescence at 480 nm. Doxorubicin (Dox), a common anticancer drug, not only causes damage to the nuclear DNA of cells but can also be rapidly inserted into the mtDNA of living cells, causing the aggregation of mtDNA nucleoids and changing the distribution of nuclear proteins (375-382). Therefore, after Dox induces mtDNA damage, morphological changes of mtDNA can be tracked in real time using the two-photon fluorescent probe CNQ, which emits red fluorescence and is localized to mtDNA. When incubated with Dox, dynamic changes in mtDNA can be observed, providing a new method for studying mtDNA damage in real time (383,384).

5. Treatment of mitochondrial diseases

In addition to primary mitochondrial disease caused by mtDNA damage, mitochondrial dysfunction occurs in a number of infectious and non-infectious diseases (262,385,386), such as inflammation, neurodegeneration, diabetes, obesity and cardiovascular disease and several therapies targeting mitochondria

have been developed (Table II). Mitochondrial transplantation and mitochondrial replacement can fundamentally address the inadequate energy supply in pathological states and have been applied in clinical settings for the treatment of pediatric congenital heart disease (385).

Leber hereditary optic neuropathy (LHON), the most common primary mitochondrial disease, is a maternally-inherited bilateral-blinding optic neuropathy mainly caused by mtDNA mutations, including m.3460G>A (MT-ND1), m.11778G>A (MT-ND4) and m.14484T>C (MT-ND6), of which m.11778G>A is the most common mutation (387,388). These mutations can affect the mitochondrial respiratory chain complex I of retinal ganglion cells, impair mitochondrial function and increase the production of reactive oxygen species, leading to apoptosis and optic nerve degeneration and atrophy, which further leads to rapidly progressive loss of binocular vision (389-391). Treatment of LHON is mostly based on ectopic expression, that is, intravitreal injection of adeno-associated viral vectors with mitochondrial targeting sequences and then guiding the translated protein into mitochondria to restore mitochondrial function, which has been successfully and safely applied to cell models. Transplant into an inducible LHON animal model that preserves retinal ganglion cells and visual function (392,393).

The mitochondrial diseases associated with mtDNA deletion mainly include chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS) and Pearson syndrome. CPEO is mostly associated with m.3243A>G(MT-TL1) deletion, which manifests as progressive paralysis of the ocular muscles, resulting in ocular movement disorders and ptosis, which usually appear in late childhood or early adulthood (394,395). KSS is a more severe syndrome than CPEO and is mostly associated with m.8993T>G (APT6) deletion. Its main clinical manifestations are progressive external ophthalmoplegia and retinitis pigmentosa, usually occurring before the age of 20 (396-399). Other symptoms may include mild skeletal muscle weakness, hearing loss, cognitive impaired cognitive function and diabetes. Pearson's syndrome is a syndrome caused by sideroblastic anemia and pancreatic exocrine insufficiency. There are very few cases (~100 cases worldwide) that may be related to the deletion of ATPase 6 and 8. Most patients die during infancy; however, a minority of patients who survive into adulthood tend to develop symptoms of KSS syndrome. Due to the double-membrane structure of mitochondria and the inability of foreign nucleic acids to recombine on endogenous mtDNA (168,400,401), there is currently no effective method to directly import nucleic acids into mitochondria and the localization of proteins to mitochondria is a routine practice in the treatment of mitochondrial diseases. In principle, expression of mitochondrial-targeted DNases that specifically recognize mutated sequences can remove mutated mtDNA, or at least reduce its abundance in a heterogeneous background. Restriction endonucleases, zinc finger nucleases and transcription activator-like effector nucleases have been tested and proven effective; these specific enzymes can be used to eliminate aberrant mtDNA and thereby reduce the rate of aberrant mtDNA in cells (402-406).

In addition, mitochondrial neurogastrointestinal encephalomyopathy, a rare mitochondrial disease, is often associated with TYMP gene mutations, manifesting as

Table II. Treatment of mitochondrial diseases.

Author, year	Mitochondrial diseases	Treatment method	Representative intervention	Mechanism	Effect on mitochondria	Application status	(Refs.)
Feng <i>et al.</i> , 2019	Primary mitochondrial disease	Edit mtDNA	AAV, CRISPR-Cas9	Reduce mtDNA damage	Protection	Pre-clinical	(379-415)
Dabravolski <i>et al.</i> , 2022							
Hamel <i>et al.</i> , 2021							
Karshovska <i>et al.</i> , 2020							
Gao <i>et al.</i> , 2019							
Grady <i>et al.</i> , 2018							
Bozi <i>et al.</i> , 2020							
Jing <i>et al.</i> , 2019							
Amore <i>et al.</i> , 2021							
Chen and Bhatti, 2021							
Mejia-Vergara <i>et al.</i> , 2020							
Newman <i>et al.</i> , 2021							
Stenton <i>et al.</i> , 2021							
Wang <i>et al.</i> , 2021							
Yu-Wai-Man <i>et al.</i> , 2020							
Heighton <i>et al.</i> , 2019							
Wu <i>et al.</i> , 2019							
Del Monte <i>et al.</i> , 2021							
Di Mambro <i>et al.</i> , 2021							
Di Nora <i>et al.</i> , 2019							
Nguyen <i>et al.</i> , 2019							
Ashton <i>et al.</i> , 2018							
Bonora <i>et al.</i> , 2019							
Ni <i>et al.</i> , 2018							
Porporato <i>et al.</i> , 2018							
Qi <i>et al.</i> , 2019							
Ramachandra <i>et al.</i> , 2020							
Soukas <i>et al.</i> , 2019							
Bonora <i>et al.</i> , 2021							
D'Angelo <i>et al.</i> , 2020							
Hirano <i>et al.</i> , 2021							
Kripps <i>et al.</i> , 2020							
Parés <i>et al.</i> , 2021							
Jackson <i>et al.</i> , 2020							

MSC-EVs

Table II. Continued.

Author, year	Mitochondrial diseases	Treatment method	Representative intervention	Mechanism	Effect on mitochondria	Application status	(Refs.)
Deng <i>et al.</i> , 2021	ATP deficiency	Nanomaterials	TPP	Mitochondrial membrane potential	Protection	Pre-clinical	(394-400, 420-436)
Le Gal <i>et al.</i> , 2021							
Bhatti <i>et al.</i> , 2021							
Grosser <i>et al.</i> , 2021							
He <i>et al.</i> , 2022							
He <i>et al.</i> , 2021							
He <i>et al.</i> , 2021							
Labarta <i>et al.</i> , 2019							
Wu <i>et al.</i> , 2019							
Del Monte <i>et al.</i> , 2021							
Nguyen <i>et al.</i> , 2019	Resveratrol	AICAR	Mitochondrial biogenesis	Protection	Have been approved	(54,395, 396,399, 400,435, 465-471)	
Ashton <i>et al.</i> , 2018							
Roth <i>et al.</i> , 2020							
Del Monte <i>et al.</i> , 2021							
Nguyen <i>et al.</i> , 2019	ATP deficiency	RTA-408	Epicatechin	Mitochondrial biogenesis	Have been approved	Pre-clinical	(394-400, 420-436)
Gabandé-Rodríguez <i>et al.</i> , 2019							
Cho <i>et al.</i> , 2020							
Liu <i>et al.</i> , 2021							
Deng <i>et al.</i> , 2020							
Gao <i>et al.</i> , 2020	Cancers	Nanomaterials	TPP	Mitochondrial membrane potential	Protection	Pre-clinical	(394-400, 420-436)
Andrieux <i>et al.</i> , 2021							
Zeng <i>et al.</i> , 2021							
Heighton <i>et al.</i> , 2019							
Wu <i>et al.</i> , 2019							
Del Monte <i>et al.</i> , 2021							
Di Mambro <i>et al.</i> , 2021							
Di Nora <i>et al.</i> , 2019							
Nguyen <i>et al.</i> , 2019							
Ashton <i>et al.</i> , 2018							
He <i>et al.</i> , 2019	ATP deficiency	RTA-408	Epicatechin	Mitochondrial biogenesis	Have been approved	Pre-clinical	(394-400, 420-436)
He <i>et al.</i> , 2020							
He <i>et al.</i> , 2020							
Zhao <i>et al.</i> , 2021							
Macdonald <i>et al.</i> , 2018							
Tan <i>et al.</i> , 2013	ATP deficiency	RTA-408	Epicatechin	Mitochondrial biogenesis	Have been approved	Pre-clinical	(394-400, 420-436)

Table II. Continued.

Author, year	Mitochondrial diseases	Treatment method	Representative intervention	Mechanism	Effect on mitochondria	Application status	(Refs.)
Lee <i>et al</i> , 2019	Graphene	MSC-EVs, mesenchymal stem cell-derived extracellular vesicles; TPP, triphenylphosphine; MMP, mitochondrial membrane potential.	Graphene				
Wallace, 2018							
Strobe and Campanella, 2018							
Wang <i>et al</i> , 2018							
Kim <i>et al</i> , 2017							
Lleonart <i>et al</i> , 2017							
Tian <i>et al</i> , 2021							
Kim <i>et al</i> , 2017							
Chen <i>et al</i> , 2017							
Jung <i>et al</i> , 2017							
Roth <i>et al</i> , 2020							
Nash <i>et al</i> , 2021							

splanchnic neuropathy and marked motor impairment, often combined with CPEO, sensorimotor polyneuropathy and white matter encephalopathy (407-409). With advances in gene editing technology, CRISPR/Cas9 has been proposed for the treatment of mitochondrial diseases, aiming to eliminate abnormal mtDNA sequences through the principles of bacterial immunology (410,411).

To treat primary mitochondrial diseases, gene therapy based on ectopic expression is still the first choice; however, the application of viral vectors in live animals to correct any gene mutation still has the following significant problems: High cost (390,412-415), carcinogenicity and immunogenicity. Non-viral vector-mediated *in situ* mitochondrial gene therapy may be a promising approach to overcome the bottleneck of existing gene therapy LHON, such as liposome-based nanoparticles, which require further investigation (416-421).

Mesenchymal stem cell-derived EVs are a promising nano-therapeutic strategy to effectively attenuate mitochondrial damage and the inflammatory response by promoting mitochondrial transcription factor A expression and preventing mtDNA damage and leakage from target cells (422).

Oxidative stress caused by mitochondrial dysfunction is one of the etiologies of metabolic disease and is a potential target for the treatment of metabolic and neurodegenerative disorders (55,168,423-426). A number of antioxidants, such as vitamin E, ubiquinone, *N*-acetylcysteine, glutathione and melatonin, can effectively scavenge mitochondrial ROS and regulate redox processes, thus alleviating or curing disease. Antibiotics (e.g., tetracyclines and actinomycins), drugs (e.g., creatine and ursodeoxycholic acid) and exercise can significantly improve oxidative stress and balance mitochondrial fission and fusion, thus increasing the number of mitochondria, contributing to the treatment of cancer (400-406,426-442). SS31 and mitoTEMPO are novel mitochondrial-targeted antioxidants that have a scavenging effect on ROS (443-446). In addition, SS31 accumulates in the mitochondrial membrane to protect and restore the mitochondrial structure without affecting healthy mitochondria (162,447-453). Thus, SS31 and mitoTEMPO have protective effects on a variety of diseases, including heart and kidney-related diseases, as well as sepsis and diabetes, which have been demonstrated in a variety of animal models (454-457). The use of nanomaterials for mitochondrial targeting therapy has become a recent focus of research. Nanomaterials are materials with at least one of three spatial dimensions at the nanometer scale (1-100 nm). They are a new generation of materials composed of nanoparticles with sizes between atoms, molecules and macroscopic systems and are widely used in the medical field owing to their large specific surface area and excellent biocompatibility. Ideally, medical nanomaterials should remain quiescent in normal tissues but accumulate precisely and act in mitochondria under pathophysiological conditions (404,458,459). Delocalized lipophilic cations (DLCs), such as triphenylphosphine (TPP) and mitochondria-penetrating peptides (MPPs), serve a major role in mitochondria-targeted therapies. DLCs can accumulate specifically in the mitochondria of tumor cells and increase their MMP, leading to altered mitochondrial membrane permeability and inducing apoptosis (56,130,400,403,428,458-470). Studies have shown that




Figure 3. The development of mitochondrial research methods. MPP, mitochondria-penetrating peptides; mPTP, mitochondrial membrane permeability transition pore; ROS, reactive oxygen species.

graphene has a large specific surface area, good targeting and high biocompatibility, making it a promising nanodelivery system (441,471-473). Mitochondrial biogenesis is driven by PCG-1 α , which can increase the number of mitochondria in the cell and thus meet the evolving energy demands of the cell, alleviating ATP deficiency in patients with mitochondrial diseases. Promoting mitochondrial biogenesis is also an important component of mitochondrial therapeutics (474). Resveratrol, 5-aminoimidazole-4-carboxamide riboside, epicatechin and RTA-408 have significant pro-mitochondrial biogenesis effects; the treatment of mice with these drugs enhances the expression of mitochondrial electron transport chain proteins and mitochondrial transcription factors and increases the abundance of mitochondrial cristae (54,401,402,405,406,441, 471-478).

6. Summary and outlook

As the powerhouses of the cell, mitochondria are at the center of cellular oxidative phosphorylation and are critical for growth and development as well as the development of a number of diseases. Mitochondrial abnormalities can cause disturbances in the intracellular environment and can lead to a variety of diseases, such as mitochondrial heart disease, mitochondrial encephalopathy, mitochondrial myopathy and even various pathologies of the reproductive and respiratory systems. Therefore, the accurate detection of mitochondrial abnormalities is essential for clinical guidance.

Since the beginning of the last century, a number of methods for mitochondrial research have been developed (Fig. 3), from the discovery of mitochondria as intracellular granular structures to the observation of mitochondrial microstructures via EM and the use of fluorescent probes to detect physiological indicators within mitochondria. The application of these methods has provided theoretical foundations for the detection and treatment of mitochondrial diseases. Accordingly, the treatment of mitochondrial diseases has gradually evolved from drug-based therapy to multidisciplinary combination therapies, such as the use of nanomaterials to precisely transport therapeutic drugs into mitochondria for targeted drug delivery, substantially improving therapeutic efficiency. However, the methods by which therapeutic efficacy is achieved still warrant investigation. The combined application of biomedicine and material science may be a promising means of detection and treatment. Notably, the specific molecular mechanism underlying the pathogenesis of the mitochondrial disease remains unclear. Current monitoring and treatment strategies cannot completely cure mitochondrial disease but only alleviate symptoms or slow disease progression. Therefore, methods for detection and treatment that are specific to the molecular mechanisms are needed. Using multi-omics and artificial intelligence, artificial mitochondrial models can be established through molecular co-assembly technology and mitochondria-targeted drugs can be screened to conduct in-depth discussions on abnormal mitochondria, which may elucidate the pathogenesis of mitochondrial diseases at the molecular level and provide new treatments for mitochondrial diseases.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Foundation of Liaoning Education Department (grant no. JCZR2020014), the Liaoning Province Key R&D Program (grant no. 2020JH2/10300141) and the 345 Talent Project of Shengjing Hospital.

Availability of data and materials

Data sharing is not applicable to this article, as no data sets were generated or analyzed during the current study.

Authors' contributions

YY wrote the first draft of this review. HS provided valuable comments on this first draft. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Akbari M, Kirkwood TBL and Bohr VA: Mitochondria in the signaling pathways that control longevity and health span. *Ageing Res Rev* 54: 100940, 2019.
- Bock FJ and Tait SWG: Mitochondria as multifaceted regulators of cell death. *Nat Rev Mol Cell Biol* 21: 85-100, 2020.
- Chakrabarty RP and Chandel NS: Mitochondria as signaling organelles control mammalian stem cell fate. *Cell Stem Cell* 28: 394-408, 2021.
- Hood DA, Memme JM, Oliveira AN and Triolo M: Maintenance of skeletal muscle mitochondria in health, exercise, and aging. *Annu Rev Physiol* 81: 19-41, 2019.
- Li L, Conradson DM, Bharat V, Kim MJ, Hsieh CH, Minhas PS, Papakyriakos AM, Durairaj AS, Ludlam A, Andreasson KI, *et al*: A mitochondrial membrane-bridging machinery mediates signal transduction of intramitochondrial oxidation. *Nat Metab* 3: 1242-1258, 2021.
- Martínez-Reyes I and Chandel NS: Mitochondrial TCA cycle metabolites control physiology and disease. *Nat Commun* 11: 102, 2020.
- Kim Hong HT, Bich Phuong TT, Thu Thuy NT, Wheatley MD and Cushman JC: Simultaneous chloroplast, mitochondria isolation and mitochondrial protein preparation for two-dimensional electrophoresis analysis of ice plant leaves under well watered and water-deficit stressed treatments. *Protein Expr Purif* 155: 86-94, 2019.
- Boussard C and Keech O: Cell type-specific isolation of mitochondria in *Arabidopsis*. *Methods Mol Biol* 2363: 13-23, 2022.
- Elekofehinti OO, Kamdem JP, Saliu TP, Famusiwa CD, Boligon A and Teixeira Rocha JB: Improvement of mitochondrial function by *Tapinanthus globifer* (A.Rich.) Tiegh. Against hepatotoxic agent in isolated rat's liver mitochondria. *J Ethnopharmacol* 242: 112026, 2019.
- Gäbelein CG, Feng Q, Sarajlic E, Zambelli T, Guillaume-Gentil O, Kornmann B and Vorholt JA: Mitochondria transplantation between living cells. *PLoS Biol* 20: e3001576, 2022.
- Lee D, Lee YH, Lee KH, Lee BS, Alishir A, Ko YJ, Kang KS and Kim KH: Aviculin isolated from *lespedeza cuneata* induce apoptosis in breast cancer cells through mitochondria-mediated caspase activation pathway. *Molecules* 25: 1708, 2020.
- Léger JL, Jogleux JL, Savadogo F, Pichaud N and Boudreau LH: Rapid isolation and purification of functional platelet mitochondria using a discontinuous percoll gradient. *Platelets* 31: 258-264, 2020.
- Léger JL, Pichaud N and Boudreau LH: Purification of functional platelet mitochondria using a discontinuous percoll gradient. *Methods Mol Biol* 2276: 57-66, 2021.
- Liao PC, Bergamini C, Fato R, Pon LA and Pallotti F: Isolation of mitochondria from cells and tissues. *Methods Cell Biol* 155: 3-31, 2020.
- Lin YT, Chen ST, Chang JC, Teoh RJ, Liu CS and Wang GJ: Green extraction of healthy and additive free mitochondria with a conventional centrifuge. *Lab Chip* 19: 3862-3869, 2019.
- Long Q, Huang L, Huang K and Yang Q: Assessing mitochondrial bioenergetics in isolated mitochondria from mouse heart tissues using oroboros 2k-oxygraph. *Methods Mol Biol* 1966: 237-246, 2019.
- Rahman MH, Xiao Q, Zhao S, Wei AC and Ho YP: Extraction of functional mitochondria based on membrane stiffness. *Methods Mol Biol* 2276: 343-355, 2021.
- Ramezani M, Samiei F and Pourahmad J: Anti-glioma effect of pseudosynanceia melanostigma venom on isolated mitochondria from glioblastoma cells. *Asian Pac J Cancer Prev* 22: 2295-2302, 2021.
- Ruzzenente B and Metodiev MD: Linear density sucrose gradients to study mitoribosomal biogenesis in tissue-specific knockout mice. *Methods Mol Biol* 2224: 47-60, 2021.
- Yang J, Cao L, Li Y, Liu H, Zhang M, Ma H, Wang B, Yuan X and Liu Q: Gracillin isolated from *reineckia carnea* induces apoptosis of A549 cells via the mitochondrial pathway. *Drug Des Devel Ther* 15: 233-243, 2021.
- Chandra K, Kumar V, Werner SE and Odom TW: Separation of stabilized MOPS gold nanostars by density gradient centrifugation. *ACS Omega* 2: 4878-4884, 2017.
- Chen BY, Sung CW, Chen C, Cheng CM, Lin DP, Huang CT and Hsu MY: Advances in exosomes technology. *Clin Chim Acta* 493: 14-19, 2019.
- Écija-Arenas Á, Román-Pizarro V and Fernández-Romero JM: Luminescence continuous flow system for monitoring the efficiency of hybrid liposomes separation using multiphase density gradient centrifugation. *Talanta* 222: 121532, 2021.
- Hu P, Fabyanic E, Kwon DY, Tang S, Zhou Z and Wu H: Dissecting cell-type composition and activity-dependent transcriptional state in mammalian brains by massively parallel single-nucleus RNA-Seq. *Mol Cell* 68: 1006-1015.e7, 2017.
- Jerri HA, Sheehan WP, Snyder CE and Velegol D: Prolonging density gradient stability. *Langmuir* 26: 4725-4731, 2010.
- Johnson ME, Montoro Bustos AR and Winchester MR: Practical utilization of spICP-MS to study sucrose density gradient centrifugation for the separation of nanoparticles. *Anal Bioanal Chem* 408: 7629-7640, 2016.
- Pužar Dominkuš P, Stenovec M, Sitar S, Lasič E, Zorec R, Plemenitaš A, Žagar E, Kreft M and Lenassi M: PKH26 labeling of extracellular vesicles: Characterization and cellular internalization of contaminating PKH26 nanoparticles. *Biochim Biophys Acta Biomembr* 1860: 1350-1361, 2018.
- Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, Zhang R, Chen R, Li T, Zhang T, *et al*: Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. *J Hepatol* 65: 700-710, 2016.
- Sugiura A, Nagashima S, Tokuyama T, Amo T, Matsuki Y, Ishido S, Kudo Y, McBride HM, Fukuda T, Matsushita N, *et al*: MITOL regulates endoplasmic reticulum-mitochondria contacts via Mitofusin2. *Mol Cell* 51: 20-34, 2013.
- Xiong B, Cheng J, Qiao Y, Zhou R, He Y and Yeung ES: Separation of nanorods by density gradient centrifugation. *J Chromatogr A* 1218: 3823-3829, 2011.
- Zheng X, Xu K, Zhou B, Chen T, Huang Y, Li Q, Wen F, Ge W, Wang J, Yu S, *et al*: A circulating extracellular vesicles-based novel screening tool for colorectal cancer revealed by shotgun and data-independent acquisition mass spectrometry. *J Extracell Vesicles* 9: 1750202, 2020.

32. Zhu J, Liu B, Wang Z, Wang D, Ni H, Zhang L and Wang Y: Exosomes from nicotine-stimulated macrophages accelerate atherosclerosis through miR-21-3p/PTEN-mediated VSMC migration and proliferation. *Theranostics* 9: 6901-6919, 2019.
33. Qattan AT, Mulvey C, Crawford M, Natale DA and Godovac-Zimmermann J: Quantitative organelle proteomics of MCF-7 breast cancer cells reveals multiple subcellular locations for proteins in cellular functional processes. *J Proteome Res* 9: 495-508, 2010.
34. Hassani M, Hellebrekers P, Chen N, van Aalst C, Bongers S, Hietbrink F, Koenderman L and Vrsekoop N: On the origin of low-density neutrophils. *J Leukoc Biol* 107: 809-818, 2020.
35. Shi W, Wang Y, Zhang C, Jin H, Zeng Z, Wei L, Tian Y, Zhang D and Sun G: Isolation and purification of immune cells from the liver. *Int Immunopharmacol* 85: 106632, 2020.
36. Grist TM, Canon CL, Fishman EK, Kohi MP and Mossa-Basha M: Short-, mid-, and long-term strategies to manage the shortage of iohexol. *Radiology* 304: 289-293, 2022.
37. Liang S, Su M, Liu B, Liu R, Zheng H, Qiu W and Zhang Z: Evaluation of blood induced influence for high-definition intravascular ultrasound (HD-IVUS). *IEEE Trans Ultrason Ferroelectr Freq Control* 69: 98-105, 2022.
38. Warwick J and Holness J: Measurement of glomerular filtration rate. *Semin Nucl Med* 52: 453-466, 2022.
39. Elgamel S, Cocucci E, Sass EJ, Mo XM, Blissett AR, Calomeni EP, Rogers KA, Woyach JA, Bhat SA, Muthusamy N, *et al*: Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant. *JCI Insight* 6: e137937, 2021.
40. Inoue T, Kusumoto S, Iio E, Ogawa S, Suzuki T, Yagi S, Kaneko A, Matsuura K, Aoyagi K and Tanaka Y: Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. *J Hepatol* 75: 302-310, 2021.
41. Tóth EÁ, Turiák L, Visnovitz T, Cserép C, Mázló A, Sódar BW, Försönits AI, Petővári G, Sebestyén A, Komlósi Z, *et al*: Formation of a protein corona on the surface of extracellular vesicles in blood plasma. *J Extracell Vesicles* 10: e12140, 2021.
42. Veerman RE, Teeuwen L, Czarnewski P, Güclüler Akpinar G, Sandberg A, Cao X, Pernemalm M, Orre LM, Gabriëlsson S and Eldh M: Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin. *J Extracell Vesicles* 10: e12128, 2021.
43. Cartuche L, Reyes-Batlle M, Sifaoui I, Arberas-Jiménez I, Piñero JE, Fernández JJ, Lorenzo-Morales J and Díaz-Marrero AR: Antiamoebic activities of indolocarbazole metabolites isolated from streptomyces sanyensis cultures. *Mar Drugs* 17: 588, 2019.
44. Jiang S, Zhang H, E, Ruan H, Ma J, Zhao X, Zhu Y, Xiu X, Han N, Li J, Zhang H, *et al*: Actinomycin V induces apoptosis associated with mitochondrial and PI3K/AKT pathways in human CRC cells. *Mar Drugs* 19: 599, 2021.
45. Li K, Liang Z, Chen W, Luo X, Fang W, Liao S, Lin X, Yang B, Wang J, Tang L, *et al*: Iakyracidins A-D, antiproliferative piericidin analogues bearing a carbonyl group or cyclic skeleton from streptomyces iakyrus SCSIO NS104. *J Org Chem* 84: 12626-12631, 2019.
46. Liu L, Zhu H, Wu W, Shen Y, Lin X, Wu Y, Liu L, Tang J, Zhou Y, Sun F and Lin HW: Neoantimycin F, a streptomyces-derived natural product induces mitochondria-related apoptotic death in human non-small cell lung cancer cells. *Front Pharmacol* 10: 1042, 2019.
47. Rawat PS, Jaiswal A, Khurana A, Bhatti JS and Navik U: Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. *Biomed Pharmacother* 139: 111708, 2021.
48. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K and Hauser CJ: Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* 464: 104-107, 2010.
49. Deng X, Liu J, Liu L, Sun X, Huang J and Dong J: Drp1-mediated mitochondrial fission contributes to baicalein-induced apoptosis and autophagy in lung cancer via activation of AMPK signaling pathway. *Int J Biol Sci* 16: 1403-1416, 2020.
50. Ma ZJ, Lu L, Yang JJ, Wang XX, Su G, Wang ZL, Chen GH, Sun HM, Wang MY and Yang Y: Laricresinol induces apoptosis in HepG2 cells via mitochondrial-mediated apoptosis pathway. *Eur J Pharmacol* 821: 1-10, 2018.
51. Ke H, Dass S, Morrissey JM, Mather MW and Vaidya AB: The mitochondrial ribosomal protein L13 is critical for the structural and functional integrity of the mitochondrion in plasmodium falciparum. *J Biol Chem* 293: 8128-8137, 2018.
52. Galvan DL, Green NH and Danesh FR: The hallmarks of mitochondrial dysfunction in chronic kidney disease. *Kidney Int* 92: 1051-1057, 2017.
53. Wiemerslage L and Lee D: Quantification of mitochondrial morphology in neurites of dopaminergic neurons using multiple parameters. *J Neurosci Methods* 262: 56-65, 2016.
54. Labarta E, de Los Santos MJ, Escribá MJ, Pellicer A and Herraiz S: Mitochondria as a tool for oocyte rejuvenation. *Fertil Steril* 111: 219-226, 2019.
55. Li WQ, Wang Z, Hao S, He H, Wan Y, Zhu C, Sun LP, Cheng G and Zheng SY: Mitochondria-targeting polydopamine nanoparticles to deliver doxorubicin for overcoming drug resistance. *ACS Appl Mater Interfaces* 9: 16793-16802, 2017.
56. Lin Y, Liu J, Bai R, Shi J, Zhu X, Liu J, Guo J, Zhang W, Liu H and Liu Z: Mitochondria-inspired nanoparticles with microenvironment-adapting capacities for on-demand drug delivery after ischemic injury. *ACS Nano* 14: 11846-11859, 2020.
57. Smith GM and Gallo G: The role of mitochondria in axon development and regeneration. *Dev Neurobiol* 78: 221-237, 2018.
58. Bastian C, Day J, Politano S, Quinn J, Brunet S and Baltan S: Preserving mitochondrial structure and motility promotes recovery of white matter after ischemia. *Neuromolecular Med* 21: 484-492, 2019.
59. Bhargava P and Schnellmann RG: Mitochondrial energetics in the kidney. *Nat Rev Nephrol* 13: 629-646, 2017.
60. Granata C, Jamnick NA and Bishop DJ: Training-induced changes in mitochondrial content and respiratory function in human skeletal muscle. *Sports Med* 48: 1809-1828, 2018.
61. Hammond K, Ryadnov MG and Hoogenboom BW: Atomic force microscopy to elucidate how peptides disrupt membranes. *Biochim Biophys Acta Biomembr* 1863: 183447, 2021.
62. Heath GR, Kots E, Robertson JL, Lansky S, Khelashvili G, Weinstein H and Scheuring S: Localization atomic force microscopy. *Nature* 594: 385-390, 2021.
63. Müller DJ, Dumitru AC, Lo Giudice C, Gaub HE, Hinterdorfer P, Hummer G, De Yoreo JJ, Dufrêne YF and Alsteens D: Atomic force microscopy-based force spectroscopy and multiparametric imaging of biomolecular and cellular systems. *Chem Rev* 121: 11701-11725, 2021.
64. Vogt N: Atomic force microscopy in super-resolution. *Nat Methods* 18: 859, 2021.
65. Kolosov VL, Sivaguru M, Huff J, Luby K, Kanakaraju K and Gaskins HR: Airyscan super-resolution microscopy of mitochondrial morphology and dynamics in living tumor cells. *Microsc Res Tech* 81: 115-128, 2018.
66. Rocha EM, De Miranda B and Sanders LH: Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. *Neurobiol Dis* 109: 249-257, 2018.
67. Szymański J, Janikiewicz J, Michalska B, Patalas-Krawczyk P, Perrone M, Ziółkowski W, Duszyński J, Pinton P, Dobrzyń A and Więckowski MR: Interaction of mitochondria with the endoplasmic reticulum and plasma membrane in calcium homeostasis, lipid trafficking and mitochondrial structure. *Int J Mol Sci* 18: 1576, 2017.
68. Adam N, Beattie TL and Riabowol K: Fluorescence microscopy methods for examining telomeres during cell aging. *Ageing Res Rev* 68: 101320, 2021.
69. Huang L, Chen H, Luo Y, Rivenson Y and Ozcan A: Recurrent neural network-based volumetric fluorescence microscopy. *Light Sci Appl* 10: 62, 2021.
70. Thiele JC, Helmerich DA, Oleksiievets N, Tsukanov R, Butkevich E, Sauer M, Nevskiy O and Enderlein J: Confocal fluorescence-lifetime single-molecule localization microscopy. *ACS Nano* 14: 14190-14200, 2020.
71. Zhang Y, Zong H, Zong C, Tan Y, Zhang M, Zhan Y and Cheng JX: Fluorescence-detected mid-infrared photothermal microscopy. *J Am Chem Soc* 143: 11490-11499, 2021.
72. Alexander JF, Seua AV, Arroyo LD, Ray PR, Wangzhou A, Heiß-Lückemann L, Schedlowski M, Price TJ, Kavelaars A and Heijnen CJ: Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits. *Theranostics* 11: 3109-3130, 2021.
73. Dumitru AC, Stommen A, Koehler M, Cloos AS, Yang J, Leclercqz A, Tyteca D and Alsteens D: Probing PIEZO1 localization upon activation using high-resolution atomic force and confocal microscopy. *Nano Lett* 21: 4950-4958, 2021.
74. Wu Y, Han X, Su Y, Glidewell M, Daniels JS, Liu J, Sengupta T, Rey-Suarez I, Fischer R, Patel A, *et al*: Multiview confocal super-resolution microscopy. *Nature* 600: 279-284, 2021.

75. Yordanov S, Neuhaus K, Hartmann R, Díaz-Pascual F, Vidakovic L, Singh PK and Drescher K: Single-objective high-resolution confocal light sheet fluorescence microscopy for standard biological sample geometries. *Biomed Opt Express* 12: 3372-3391, 2021.
76. Zhao Y, Raghuram A, Kim HK, Hielscher AH, Robinson JT and Veeraraghavan A: High resolution, deep imaging using confocal time-of-flight diffuse optical tomography. *IEEE Trans Pattern Anal Mach Intell* 43: 2206-2219, 2021.
77. Dalecká M, Sabó J, Backová L, Rösel D, Brábek J, Benda A and Tolde O: Invadopodia structure in 3D environment resolved by near-infrared branding protocol combining correlative confocal and FIB-SEM microscopy. *Int J Mol Sci* 22: 7805, 2021.
78. Guo R, Barnea I and Shaked NT: Limited-angle tomographic phase microscopy utilizing confocal scanning fluorescence microscopy. *Biomed Opt Express* 12: 1869-1881, 2021.
79. Lamers MM, van der Vaart J, Knoops K, Riesebosch S, Breugem TI, Myktyyn AZ, Beumer J, Schipper D, Bezstarosti K, Koopman CD, *et al*: An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. *EMBO J* 40: e105912, 2021.
80. Messal HA, Almagro J, Zaw Thin M, Tedeschi A, Ciccarelli A, Blackie L, Anderson KI, Miguel-Aliaga I, van Rheenen J and Behrens A: Antigen retrieval and clearing for whole-organ immunofluorescence by FLASH. *Nat Protoc* 16: 239-262, 2021.
81. Miyashita L, Foley G, Gill I, Gillmore G, Grigg J and Wertheim D: Confocal microscopy 3D imaging of diesel particulate matter. *Environ Sci Pollut Res Int* 28: 30384-30389, 2021.
82. Restall BS, Kedarisetti P, Haven NJM, Martell MT and Zemp RJ: Multimodal 3D photoacoustic remote sensing and confocal fluorescence microscopy imaging. *J Biomed Opt* 26: 096501, 2021.
83. Rodríguez-Gallardo S, Kurokawa K, Sabido-Bozo S, Cortes-Gomez A, Perez-Linero AM, Aguilera-Romero A, Lopez S, Waga M, Nakano A and Muñoz M: Assay for dual cargo sorting into endoplasmic reticulum exit sites imaged by 3D super-resolution confocal live imaging microscopy (SCLIM). *PLoS One* 16: e0258111, 2021.
84. Durand MJ, Ait-Aissa K, Levchenko V, Staruschenko A, Gutterman DD and Beyer AM: Visualization and quantification of mitochondrial structure in the endothelium of intact arteries. *Cardiovasc Res* 115: 1546-1556, 2019.
85. Bartolák-Suki E and Suki B: Tuning mitochondrial structure and function to criticality by fluctuation-driven mechanotransduction. *Sci Rep* 10: 407, 2020.
86. Chandhok G, Lazarou M and Neumann B: Structure, function, and regulation of mitofusin-2 in health and disease. *Biol Rev Camb Philos Soc* 93: 933-949, 2018.
87. Kowaltowski AJ, Menezes-Filho SL, Assali EA, Gonçalves IG, Cabral-Costa JV, Abreu P, Miller N, Nolasco P, Laurindo FRM, Bruni-Cardoso A and Shirihai OS: Mitochondrial morphology regulates organellar Ca^{2+} uptake and changes cellular Ca^{2+} homeostasis. *FASEB J* 33: 13176-13188, 2019.
88. Csordás G, Weaver D and Hajnóczky G: Endoplasmic reticulum-mitochondrial contactology: Structure and signaling functions. *Trends Cell Biol* 28: 523-540, 2018.
89. Xie LL, Shi F, Tan Z, Li Y, Bode AM and Cao Y: Mitochondrial network structure homeostasis and cell death. *Cancer Sci* 109: 3686-3694, 2018.
90. Correia-Álvarez E, Keating JE, Glish G, Tarran R and Sassano MF: Reactive oxygen species, mitochondrial membrane potential, and cellular membrane potential are predictors of E-liquid induced cellular toxicity. *Nicotine Tob Res* 22 (Suppl 1): S4-S13, 2020.
91. Zhou Y, Long Q, Wu H, Li W, Qi J, Wu Y, Xiang G, Tang H, Yang L, Chen K, *et al*: Topology-dependent, bifurcated mitochondrial quality control under starvation. *Autophagy* 16: 562-574, 2020.
92. Du R, Bei H, Jia L, Huang C, Chen Q, Wang J, Wu F, Chen J and Bo H: A low-cost, accurate method for detecting reticulocytes at different maturation stages based on changes in the mitochondrial membrane potential. *J Pharmacol Toxicol Methods* 101: 106664, 2020.
93. Ganta KK, Mandal A and Chaubey B: Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity. *Cell Biol Toxicol* 33: 69-82, 2017.
94. Dreier DA, Denslow ND and Martyniuk CJ: Computational in vitro toxicology uncovers chemical structures impairing mitochondrial membrane potential. *J Chem Inf Model* 59: 702-712, 2019.
95. Lee JY, Lim W, Ham J, Kim J, You S and Song G: Ivermectin induces apoptosis of porcine trophectoderm and uterine luminal epithelial cells through loss of mitochondrial membrane potential, mitochondrial calcium ion overload, and reactive oxygen species generation. *Pestic Biochem Physiol* 159: 144-153, 2019.
96. Tao L, Liu X, Da W, Tao Z and Zhu Y: Pycnogenol achieves neuroprotective effects in rats with spinal cord injury by stabilizing the mitochondrial membrane potential. *Neurol Res* 42: 597-604, 2020.
97. Haider SZ, Mohanraj N, Markandeya YS, Joshi PG and Mehta B: Picture perfect: Imaging mitochondrial membrane potential changes in retina slices with minimal stray fluorescence. *Exp Eye Res* 202: 108318, 2021.
98. Zhang G, Yang W, Zou P, Jiang F, Zeng Y, Chen Q, Sun L, Yang H, Zhou N, Wang X, *et al*: Mitochondrial functionality modifies human sperm acrosin activity, acrosome reaction capability and chromatin integrity. *Hum Reprod* 34: 3-11, 2019.
99. Sakthivel R, Malar DS and Devi KP: Phytol shows anti-angiogenic activity and induces apoptosis in A549 cells by depolarizing the mitochondrial membrane potential. *Biomed Pharmacother* 105: 742-752, 2018.
100. Alyasin A, Momeni HR and Mahdih M: Aquaporin3 expression and the potential role of aquaporins in motility and mitochondrial membrane potential in human spermatozoa. *Andrologia* 52: e13588, 2020.
101. Alpert NM, Guehl N, Ptaszek L, Pelletier-Galarneau M, Ruskin J, Mansour MC, Wooten D, Ma C, Takahashi K, Zhou Y, *et al*: Quantitative in vivo mapping of myocardial mitochondrial membrane potential. *PLoS One* 13: e0190968, 2018.
102. Kuwahara Y, Roudkenar MH, Suzuki M, Urushihara Y, Fukumoto M, Saito Y and Fukumoto M: The Involvement of mitochondrial membrane potential in cross-resistance between radiation and docetaxel. *Int J Radiat Oncol Biol Phys* 96: 556-565, 2016.
103. Marcondes NA, Terra SR, Lasta CS, Hlavac NRC, Dalmolin ML, Lacerda LA, Faulhaber GAM and González FHD: Comparison of JC-1 and MitoTracker probes for mitochondrial viability assessment in stored canine platelet concentrates: A flow cytometry study. *Cytometry A* 95: 214-218, 2019.
104. Poznanski RR, Cacha LA, Ali J, Rizvi ZH, Yupapin P, Salleh SH and Bandyopadhyay A: Induced mitochondrial membrane potential for modeling solitonic conduction of electrotonic signals. *PLoS One* 12: e0183677, 2017.
105. Georgakopoulos ND, Wells G and Campanella M: The pharmacological regulation of cellular mitophagy. *Nat Chem Biol* 13: 136-146, 2017.
106. Bikas A, Jensen K, Patel A, Costello J, Kaltsas G, Hoperia V, Wartofsky L, Burman K and Vasko V: Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells. *Int J Oncol* 55: 7-20, 2019.
107. Gloria A, Wegher L, Carluccio A, Valorz C, Robbe D and Contri A: Factors affecting staining to discriminate between bull sperm with greater and lesser mitochondrial membrane potential. *Anim Reprod Sci* 189: 51-59, 2018.
108. Saraf KK, Kumaresan A, Chhillar S, Nayak S, Lathika S, Datta TK, Gahlot SC, Karan P, Verma K and Mohanty TK: Spermatozoa with high mitochondrial membrane potential and low tyrosine phosphorylation preferentially bind to oviduct explants in the water buffalo (*Bubalus bubalis*). *Anim Reprod Sci* 180: 30-36, 2017.
109. Cano M, Datta S, Wang L, Liu T, Flores-Bellver M, Sachdeva M, Sinha D and Handa JT: Nrf2 deficiency decreases NADPH from impaired IDH shuttle and pentose phosphate pathway in retinal pigmented epithelial cells to magnify oxidative stress-induced mitochondrial dysfunction. *Aging Cell* 20: e13444, 2021.
110. El Manaa W, Duplan E, Goiran T, Lauritzen I, Vaillant Beuchot L, Lacas-Gervais S, Morais VA, You H, Qi L, Salazar M, *et al*: Transcription- and phosphorylation-dependent control of a functional interplay between XBP1s and PINK1 governs mitophagy and potentially impacts Parkinson disease pathophysiology. *Autophagy* 17: 4363-4385, 2021.
111. Franco-Iborra S, Plaza-Zabala A, Montpeyo M, Sebastian D, Vila M and Martinez-Vicente M: Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease. *Autophagy* 17: 672-689, 2021.
112. Hamilton K, Krause K, Badr A, Daily K, Estfanous S, Eltobgy M, Khweek AA, Anne MNK, Carafice C, Baetzhold D, *et al*: Defective immunometabolism pathways in cystic fibrosis macrophages. *J Cyst Fibros* 20: 664-672, 2021.

113. Rabinovich-Nikitin I, Rasouli M, Reitz CJ, Posen I, Margulets V, Dhingra R, Khatua TN, Thliveris JA, Martino TA and Kirshenbaum LA: Mitochondrial autophagy and cell survival is regulated by the circadian clock gene in cardiac myocytes during ischemic stress. *Autophagy* 17: 3794-3812, 2021.
114. Rovini A, Heslop K, Hunt EG, Morris ME, Fang D, Gooz M, Gerencser AA and Maldonado EN: Quantitative analysis of mitochondrial membrane potential heterogeneity in unsynchronized and synchronized cancer cells. *FASEB J* 35: e21148, 2021.
115. Samuvel DJ, Li L, Krishnasamy Y, Gooz M, Takemoto K, Woster PM, Lemasters JJ and Zhong Z: Mitochondrial depolarization after acute ethanol treatment drives mitophagy in living mice. *Autophagy*: 1-15, 2022 (Epub ahead of print).
116. Wang Q and Hutt KJ: Evaluation of mitochondria in mouse oocytes following cisplatin exposure. *J Ovarian Res* 14: 65, 2021.
117. Yazdankhah M, Ghosh S, Shang P, Stepicheva N, Hose S, Liu H, Chamling X, Tian S, Sullivan MLG, Calderon MJ, *et al*: BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes. *Autophagy* 17: 3140-3159, 2021.
118. Young VC and Artigas P: Displacement of the Na⁺/K⁺ pump's transmembrane domains demonstrates conserved conformational changes in P-type 2 ATPases. *Proc Natl Acad Sci USA* 118: e2019317118, 2021.
119. Cui Y, Duan W, Jin Y, Wo F, Xi F and Wu J: Graphene quantum dot-decorated luminescent porous silicon dressing for theranostics of diabetic wounds. *Acta Biomater* 131: 544-554, 2021.
120. Kambe Y and Yamaoka T: Initial immune response to a FRET-based MMP sensor-immobilized silk fibroin hydrogel in vivo. *Acta Biomater* 130: 199-210, 2021.
121. Feng R, Guo L, Fang J, Jia Y, Wang X, Wei Q and Yu X: Construction of the FRET pairs for the visualization of mitochondria membrane potential in dual emission colors. *Anal Chem* 91: 3704-3709, 2019.
122. Lee H, Kim SJ, Shin H and Kim YP: Collagen-immobilized extracellular FRET reporter for visualizing protease activity secreted by living cells. *ACS Sens* 5: 655-664, 2020.
123. Liu L, Chu H, Yang J, Sun Y, Ma P and Song D: Construction of a magnetic-fluorescent-plasmonic nanosensor for the determination of MMP-2 activity based on SERS-fluorescence dual-mode signals. *Biosens Bioelectron* 212: 114389, 2022.
124. Zhan Y, Ling S, Huang H, Zhang Y, Chen G, Huang S, Li C, Guo W and Wang Q: Rapid unperturbed-tissue analysis for intraoperative cancer diagnosis using an enzyme-activated NIR-II nanoprobe. *Angew Chem Int Ed Engl* 60: 2637-2642, 2021.
125. Wang C, Wang G, Li X, Wang K, Fan J, Jiang K, Guo Y and Zhang H: Highly sensitive fluorescence molecular switch for the ratio monitoring of trace change of mitochondrial membrane potential. *Anal Chem* 89: 11514-11519, 2017.
126. Rao M, Jaber BL and Balakrishnan VS: Chronic kidney disease and acquired mitochondrial myopathy. *Curr Opin Nephrol Hypertens* 27: 113-120, 2018.
127. Zhu SC, Chen C, Wu YN, Ahmed M, Kitmitto A, Greenstein AS, Kim SJ, Shao YF and Zhang YH: Cardiac complex II activity is enhanced by fat and mediates greater mitochondrial oxygen consumption following hypoxic re-oxygenation. *Pflugers Arch* 472: 367-374, 2020.
128. Kurhaluk N, Lukash O, Nosar V, Portnychenko A, Portnichenko V, Wszedybyl-Winkowska M and Winkowski PJ: Liver mitochondrial respiratory plasticity and oxygen uptake evoked by cobalt chloride in rats with low and high resistance to extreme hypobaric hypoxia. *Can J Physiol Pharmacol* 97: 392-399, 2019.
129. Acetoze G, Champagne J, Ramsey JJ and Rossow HA: Liver mitochondrial oxygen consumption and efficiency of milk production in lactating Holstein cows supplemented with copper, manganese and zinc. *J Anim Physiol Anim Nutr (Berl)* 102: e787-e797, 2018.
130. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J and Dwinell MB: A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. *Redox Biol* 14: 316-327, 2018.
131. Banh RS, Iorio C, Marcotte R, Xu Y, Cojocari D, Rahman AA, Pawling J, Zhang W, Sinha A, Rose CM, *et al*: PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia. *Nat Cell Biol* 18: 803-813, 2016.
132. Campos JC, Queliconi BB, Bozi LHM, Bechara LRG, Dourado PMM, Andres AM, Jannig PR, Gomes KMS, Zambelli VO, Rocha-Resende C, *et al*: Exercise reestablishes autophagic flux and mitochondrial quality control in heart failure. *Autophagy* 13: 1304-1317, 2017.
133. Rossow HA, Acetoze G, Champagne J and Ramsey JJ: Measuring liver mitochondrial oxygen consumption and proton leak kinetics to estimate mitochondrial respiration in holstein dairy cattle. *J Vis Exp*, 2018.
134. Morimoto N, Hashimoto S, Yamanaka M, Nakano T, Satoh M, Nakaoka Y, Iwata H, Fukui A, Morimoto Y and Shibahara H: Mitochondrial oxygen consumption rate of human embryos declines with maternal age. *J Assist Reprod Genet* 37: 1815-1821, 2020.
135. Darr CR, Cortopassi GA, Datta S, Varner DD and Meyers SA: Mitochondrial oxygen consumption is a unique indicator of stallion spermatozoal health and varies with cryopreservation media. *Theriogenology* 86: 1382-1392, 2016.
136. Müller ME, Vikstrom S, König M, Schlichting R, Zarfl C, Zwiener C and Escher BI: Mitochondrial toxicity of selected micropollutants, their mixtures, and surface water samples measured by the oxygen consumption rate in cells. *Environ Toxicol Chem* 38: 1000-1011, 2019.
137. Thomas LW and Ashcroft M: Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. *Cell Mol Life Sci* 76: 1759-1777, 2019.
138. Espinosa JA, Pohan G, Arkin MR and Markossian S: Real-time assessment of mitochondrial toxicity in HepG2 cells using the Seahorse extracellular flux analyzer. *Curr Protoc* 1: e75, 2021.
139. Fu Y, Wang D, Wang H, Cai M, Li C, Zhang X, Chen H, Hu Y, Zhang X, Ying M, *et al*: TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis, and a growth-promoting metabolic shift toward glycolysis in glioblastoma. *Neuro Oncol* 22: 240-252, 2020.
140. Gu X, Ma Y, Liu Y and Wan Q: Measurement of mitochondrial respiration in adherent cells by Seahorse XF96 cell mito stress Test. *STAR Protoc* 2: 100245, 2021.
141. Eagleson KL, Villaneuva M, Southern RM and Levitt P: Proteomic and mitochondrial adaptations to early-life stress are distinct in juveniles and adults. *Neurobiol Stress* 13: 100251, 2020.
142. Maremnda KP, Sundar IK and Rahman I: Role of inner mitochondrial protein OPA1 in mitochondrial dysfunction by tobacco smoking and in the pathogenesis of COPD. *Redox Biol* 45: 102055, 2021.
143. Nishida M, Yamashita N, Ogawa T, Koseki K, Warabi E, Ohue T, Komatsu M, Matsushita H, Kakimi K, Kawakami E, *et al*: Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes. *J Immunother Cancer* 9: e002954, 2021.
144. Nishida Y, Nawaz A, Kado T, Takikawa A, Igarashi Y, Onogi Y, Wada T, Sasaoka T, Yamamoto S, Sasahara M, *et al*: Astaxanthin stimulates mitochondrial biogenesis in insulin resistant muscle via activation of AMPK pathway. *J Cachexia Sarcopenia Muscle* 11: 241-258, 2020.
145. Sabogal-Guáqueta AM, Hobbie F, Keerthi A, Oun A, Kortholt A, Boddeke E and Dolga A: Linalool attenuates oxidative stress and mitochondrial dysfunction mediated by glutamate and NMDA toxicity. *Biomed Pharmacother* 118: 109295, 2019.
146. Tian T, Zhang Y, Wu T, Yang L, Chen C, Li N, Li Y, Xu S, Fu Z, Cui X, *et al*: miRNA profiling in the hippocampus of attention-deficit/hyperactivity disorder rats. *J Cell Biochem* 120: 3621-3629, 2019.
147. Ooi K, Hu L, Feng Y, Han C, Ren X, Qian X, Huang H, Chen S, Shi Q, Lin H, *et al*: Sigma-1 receptor activation suppresses microglia M1 polarization via regulating endoplasmic reticulum-mitochondria contact and mitochondrial functions in stress-induced hypertension rats. *Mol Neurobiol* 58: 6625-6646, 2021.
148. Shetty T, Park B and Corson TW: Measurement of mitochondrial respiration in the murine retina using a Seahorse extracellular flux analyzer. *STAR Protoc* 2: 100533, 2021.
149. Wang SH, Zhu XL, Wang F, Chen SX, Chen ZT, Qiu Q, Liu WH, Wu MX, Deng BQ, Xie Y, *et al*: LncRNA H19 governs mitophagy and restores mitochondrial respiration in the heart through Pink1/Parkin signaling during obesity. *Cell Death Dis* 12: 557, 2021.
150. Andersen JV, Jakobsen E, Waagepetersen HS and Aldana BI: Distinct differences in rates of oxygen consumption and ATP synthesis of regionally isolated non-synaptic mouse brain mitochondria. *J Neurosci Res* 97: 961-974, 2019.

151. Hubbard WB, Joseph B, Spry M, Vekaria HJ, Saatman KE and Sullivan PG: Acute mitochondrial impairment underlies prolonged cellular dysfunction after repeated mild traumatic brain injuries. *J Neurotrauma* 36: 1252-1263, 2019.
152. McAlpin BR, Mahalingam R, Singh AK, Dharmaraj S, Chrisikos TT, Boukelmoune N, Kavalaars A and Heijnen CJ: HDAC6 inhibition reverses long-term doxorubicin-induced cognitive dysfunction by restoring microglia homeostasis and synaptic integrity. *Theranostics* 12: 603-619, 2022.
153. Raut S, Patel R and Al-Ahmad AJ: Presence of a mutation in PSEN1 or PSEN2 gene is associated with an impaired brain endothelial cell phenotype in vitro. *Fluids Barriers CNS* 18: 3, 2021.
154. Algieri C, Trombetti F, Pagliarini A, Ventrella V and Nesci S: The mitochondrial F_1F_0 -ATPase exploits the dithiol redox state to modulate the permeability transition pore. *Arch Biochem Biophys* 712: 109027, 2021.
155. Sun C, Liu X, Wang B, Wang Z, Liu Y, Di C, Si J, Li H, Wu Q, Xu D, *et al*: Endocytosis-mediated mitochondrial transplantation: Transferring normal human astrocytic mitochondria into glioma cells rescues aerobic respiration and enhances radiosensitivity. *Theranostics* 9: 3595-3607, 2019.
156. Sun JY, Zhao SJ, Wang HB, Hou YJ, Mi QJ, Yang MF, Yuan H, Ni QB, Sun BL and Zhang ZY: Ifenprodil improves long-term neurologic deficits through antagonizing glutamate-induced excitotoxicity after experimental subarachnoid hemorrhage. *Transl Stroke Res* 12: 1067-1080, 2021.
157. Boyman L, Karbowski M and Lederer WJ: Regulation of mitochondrial ATP production: Ca^{2+} signaling and quality control. *Trends Mol Med* 26: 21-39, 2020.
158. Bravo-Sagua R, Parra V, López-Crisosto C, Díaz P, Quest AF and Lavandero S: Calcium transport and signaling in mitochondria. *Compr Physiol* 7: 623-634, 2017.
159. Marchi S, Patergnani S, Missiroli S, Morciano G, Rimessi A, Wiekowski MR, Giorgi C and Pinton P: Mitochondrial and endoplasmic reticulum calcium homeostasis and cell death. *Cell Calcium* 69: 62-72, 2018.
160. Chow J, Rahman J, Achermann JC, Dattani MT and Rahman S: Mitochondrial disease and endocrine dysfunction. *Nat Rev Endocrinol* 13: 92-104, 2017.
161. Cieluch A, Uruska A and Zozulinska-Ziolkiewicz D: Can we prevent mitochondrial dysfunction and diabetic cardiomyopathy in type 1 diabetes mellitus? Pathophysiology and treatment options. *Int J Mol Sci* 21: 2852, 2020.
162. Ding XW, Robinson M, Li R, Aldhowayan H, Geetha T and Babu JR: Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in diabetes mellitus and Alzheimer's disease. *Pharmacol Res* 171: 105783, 2021.
163. Fisher JJ, Vanderpeet CL, Bartho LA, McKeating DR, Cuffe JSM, Holland OJ and Perkins AV: Mitochondrial dysfunction in placental trophoblast cells experiencing gestational diabetes mellitus. *J Physiol* 599: 1291-1305, 2021.
164. Jelenik T and Roden M: Mitochondrial plasticity in obesity and diabetes mellitus. *Antioxid Redox Signal* 19: 258-268, 2013.
165. Rovira-Llopis S, Bañuls C, Diaz-Morales N, Hernandez-Mijares A, Rocha M and Victor VM: Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. *Redox Biol* 11: 637-645, 2017.
166. Zhao H, Li T, Wang K, Zhao F, Chen J, Xu G, Zhao J, Li T, Chen L, Li L, *et al*: AMPK-mediated activation of MCU stimulates mitochondrial Ca^{2+} entry to promote mitotic progression. *Nat Cell Biol* 21: 476-486, 2019.
167. Calvo-Rodriguez M, Hou SS, Snyder AC, Kharitonova EK, Russ AN, Das S, Fan Z, Muzikansky A, Garcia-Alloza M, Serrano-Pozo A, *et al*: Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease. *Nat Commun* 11: 2146, 2020.
168. Bhatti JS, Bhatti GK and Reddy PH: Mitochondrial dysfunction and oxidative stress in metabolic disorders-a step towards mitochondria based therapeutic strategies. *Biochim Biophys Acta Mol Basis Dis* 1863: 1066-1077, 2017.
169. Guo Q, Bi J, Wang H and Zhang X: Mycobacterium tuberculosis ESX-1-secreted substrate protein EspC promotes mycobacterial survival through endoplasmic reticulum stress-mediated apoptosis. *Emerg Microbes Infect* 10: 19-36, 2021.
170. Galla L, Vajente N, Pendin D, Pizzo P, Pozzan T and Greotti E: Generation and characterization of a new FRET-Based Ca^{2+} sensor targeted to the nucleus. *Int J Mol Sci* 22: 9945, 2021.
171. Isshiki M, Nishimoto M, Mizuno R and Fujita T: FRET-based sensor analysis reveals caveolae are spatially distinct Ca^{2+} stores in endothelial cells. *Cell Calcium* 54: 395-403, 2013.
172. Laskaratou D, Fernández GS, Coucke Q, Fron E, Rocha S, Hofkens J, Hendrix J and Mizuno H: Quantification of FRET-induced angular displacement by monitoring sensitized acceptor anisotropy using a dim fluorescent donor. *Nat Commun* 12: 2541, 2021.
173. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K and Miyawaki A: A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. *Nat Biotechnol* 20: 87-90, 2002.
174. Ucar H, Watanabe S, Noguchi J, Morimoto Y, Iino Y, Yagishita S, Takahashi N and Kasai H: Mechanical actions of dendritic-spine enlargement on presynaptic exocytosis. *Nature* 600: 686-689, 2021.
175. Yoon S, Pan Y, Shung K and Wang Y: FRET-based Ca^{2+} biosensor single cell imaging interrogated by high-frequency ultrasound. *Sensors (Basel)* 20: 4998, 2020.
176. Chen J, Qiu M, Zhang S, Li B, Li D, Huang X, Qian Z, Zhao J, Wang Z and Tang D: A calcium phosphate drug carrier loading with 5-fluorouracil achieving a synergistic effect for pancreatic cancer therapy. *J Colloid Interface Sci* 605: 263-273, 2022.
177. Fan Y and Simmen T: Mechanistic connections between endoplasmic reticulum (ER) Redox Control And Mitochondrial Metabolism. *Cells* 8: 1071, 2019.
178. Shoshan-Barmatz V, Nahon-Crystal E, Shteiinfer-Kuzmine A and Gupta R: VDAC1, mitochondrial dysfunction, and Alzheimer's disease. *Pharmacol Res* 131: 87-101, 2018.
179. Country MW and Jonz MG: Mitochondrial KATP channels stabilize intracellular Ca^{2+} during hypoxia in retinal horizontal cells of goldfish (*Carassius auratus*). *J Exp Biol* 224: jeb242634, 2021.
180. Davidson SM, Padró T, Bollini S, Vilahur G, Duncker DJ, Evans PC, Guzik T, Hofer IE, Waltenberger J, Wojta J and Weber C: Progress in cardiac research: From rebooting cardiac regeneration to a complete cell atlas of the heart. *Cardiovasc Res* 117: 2161-2174, 2021.
181. Leduc-Gaudet JP, Hussain SNA, Barreiro E and Gouspillou G: Mitochondrial dynamics and mitophagy in skeletal muscle health and aging. *Int J Mol Sci* 22: 8179, 2021.
182. Li S, Chen J, Liu M, Chen Y, Wu Y, Li Q, Ma T, Gao J, Xia Y, Fan M, *et al*: Protective effect of HINT2 on mitochondrial function via repressing MCU complex activation attenuates cardiac microvascular ischemia-reperfusion injury. *Basic Res Cardiol* 116: 65, 2021.
183. Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, von Haehling S, Jamialahmadi T and Sahebkar A: Effects of statins on mitochondrial pathways. *J Cachexia Sarcopenia Muscle* 12: 237-251, 2021.
184. Nakamura T, Ogawa M, Kojima K, Takayanagi S, Ishihara S, Hattori K, Naguro I and Ichijo H: The mitochondrial Ca^{2+} uptake regulator, MICU1, is involved in cold stress-induced ferroptosis. *EMBO Rep* 22: e51532, 2021.
185. Chen M, Mu L, Wang S, Cao X, Liang S, Wang Y, She G, Yang J, Wang Y and Shi W: A single silicon nanowire-based ratiometric biosensor for Ca^{2+} at various locations in a neuron. *ACS Chem Neurosci* 11: 1283-1290, 2020.
186. Jiang Y, Fang Y, Ye Y, Xu X, Wang B, Gu J, Aschner M, Chen J and Lu R: Anti-cancer effects of 3,3'-diindolylmethane on human hepatocellular carcinoma cells is enhanced by calcium ionophore: The role of cytosolic Ca^{2+} and p38 MAPK. *Front Pharmacol* 10: 1167, 2019.
187. Mata-Martínez E, Sánchez-Tusie AA, Darszon A, Mayorga LS, Treviño CL and De Blas GA: Epac activation induces an extracellular Ca^{2+} -independent Ca^{2+} wave that triggers acrosome reaction in human spermatozoa. *Andrology* 9: 1227-1241, 2021.
188. Wacquier B, Combettes L and Dupont G: Dual dynamics of mitochondrial permeability transition pore opening. *Sci Rep* 10: 3924, 2020.
189. Nesci S, Trombetti F, Ventrella V and Pagliarini A: From the Ca^{2+} -activated F_1F_0 -ATPase to the mitochondrial permeability transition pore: An overview. *Biochimie* 152: 85-93, 2018.
190. Cui Y, Pan M, Ma J, Song X, Cao W and Zhang P: Recent progress in the use of mitochondrial membrane permeability transition pore in mitochondrial dysfunction-related disease therapies. *Mol Cell Biochem* 476: 493-506, 2021.
191. Chinopoulos C: Mitochondrial permeability transition pore: Back to the drawing board. *Neurochem Int* 117: 49-54, 2018.
192. Briston T, Selwood DL, Szabadkai G and Duchon MR: Mitochondrial permeability transition: A molecular lesion with multiple drug targets. *Trends Pharmacol Sci* 40: 50-70, 2019.
193. Rottenberg H and Hoek JB: The path from mitochondrial ROS to aging runs through the mitochondrial permeability transition pore. *Aging Cell* 16: 943-955, 2017.

194. Zhou B, Kreuzer J, Kumsta C, Wu L, Kamer KJ, Cedillo L, Zhang Y, Li S, Kacergis MC, Webster CM, *et al*: Mitochondrial permeability uncouples elevated autophagy and lifespan extension. *Cell* 177: 299-314.e16, 2019.
195. Baines CP and Gutiérrez-Aguilar M: The still uncertain identity of the channel-forming unit(s) of the mitochondrial permeability transition pore. *Cell Calcium* 73: 121-130, 2018.
196. Ying Z, Xiang G, Zheng L, Tang H, Duan L, Lin X, Zhao Q, Chen K, Wu Y, Xing G, *et al*: Short-term mitochondrial permeability transition pore opening modulates histone lysine methylation at the early phase of somatic cell reprogramming. *Cell Metab* 28: 935-945.e5, 2018.
197. Burke PJ: Mitochondria, bioenergetics and apoptosis in cancer. *Trends Cancer* 3: 857-870, 2017.
198. Pérez MJ, Ponce DP, Aranguiz A, Behrens MI and Quintanilla RA: Mitochondrial permeability transition pore contributes to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer's disease. *Redox Biol* 19: 290-300, 2018.
199. Kalani K, Yan SF and Yan SS: Mitochondrial permeability transition pore: A potential drug target for neurodegeneration. *Drug Discov Today* 23: 1983-1989, 2018.
200. Naryzhnaya NV, Maslov LN and Oeltgen PR: Pharmacology of mitochondrial permeability transition pore inhibitors. *Drug Dev Res* 80: 1013-1030, 2019.
201. Shah SS, Lannon H, Dias L, Zhang JY, Alper SL, Pollak MR and Friedman DJ: APOL1 kidney risk variants induce cell death via mitochondrial translocation and opening of the mitochondrial permeability transition pore. *J Am Soc Nephrol* 30: 2355-2368, 2019.
202. Gao G, Wang Z, Lu L, Duan C, Wang X and Yang H: Morphological analysis of mitochondria for evaluating the toxicity of α -synuclein in transgenic mice and isolated preparations by atomic force microscopy. *Biomed Pharmacother* 96: 1380-1388, 2017.
203. Ghosh P, Bhoomik A, Saha S, Mukherjee S, Azmi S, Ghosh JK and Dungdung SR: Spermicidal efficacy of VRP, a synthetic cationic antimicrobial peptide, inducing apoptosis and membrane disruption. *J Cell Physiol* 233: 1041-1050, 2018.
204. Jiang S, Zu Y, Wang Z, Zhang Y and Fu Y: Involvement of mitochondrial permeability transition pore opening in 7-xylosyl-10-deacetylpaclitaxel-induced apoptosis. *Planta Med* 77: 1005-1012, 2011.
205. Tricaud N, Gautier B, Berthelot J, Gonzalez S and Van Hameren G: Traumatic and diabetic schwann cell demyelination is triggered by a transient mitochondrial calcium release through voltage dependent anion channel 1. *Biomedicines* 10: 1447, 2022.
206. Mukherjee R, Mareninova OA, Odinkova IV, Huang W, Murphy J, Chvanov M, Javed MA, Wen L, Booth DM, Cane MC, *et al*: Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: Inhibition prevents acute pancreatitis by protecting production of ATP. *Gut* 65: 1333-1346, 2016.
207. Urbani A, Giorgio V, Carrer A, Franchin C, Arrigoni G, Jiko C, Abe K, Maeda S, Shinzawa-Itoh K, Bogers JFM, *et al*: Purified F-ATP synthase forms a Ca^{2+} -dependent high-conductance channel matching the mitochondrial permeability transition pore. *Nat Commun* 10: 4341, 2019.
208. Aqawi M, Sionov RV, Gallily R, Friedman M and Steinberg D: Anti-bacterial properties of cannabigerol toward streptococcus mutans. *Front Microbiol* 12: 656471, 2021.
209. Asperti M, Bellini S, Grillo E, Gryzik M, Cantamessa L, Ronca R, Maccarinelli F, Salvi A, De Petro G, Arosio P, *et al*: H-ferritin suppression and pronounced mitochondrial respiration make hepatocellular carcinoma cells sensitive to RSL3-induced ferroptosis. *Free Radic Biol Med* 169: 294-303, 2021.
210. Daniyal M, Liu Y, Yang Y, Xiao F, Fan J, Yu H, Qiu Y, Liu B, Wang W and Yuhui Q: Anti-gastric cancer activity and mechanism of natural compound 'Heilaohulignan C' isolated from *Kadsura coccinea*. *Phytother Res* 35: 3977-3987, 2021.
211. Datki Z, Acs E, Balazs E, Sovany T, Csoka I, Zsuga K, Kalman J and Galik-Olah Z: Exogenic production of bioactive filamentous copolymer by monogonant rotifers. *Ecotoxicol Environ Saf* 208: 111666, 2021.
212. Ge Y, Wang C, Zhang W, Lai S, Wang D and Wang L: Coassembly behavior and rheological properties of a β -hairpin peptide with dicarboxylates. *Langmuir* 37: 11657-11664, 2021.
213. He A, Wang L, Wang Q, Luan W and Qi F: Protective effects of micronized fat against ultraviolet B-induced photoaging. *Plast Reconstr Surg* 145: 712-720, 2020.
214. Jiang Q, Su DY, Wang ZZ, Liu C, Sun YN, Cheng H, Li XM and Yan B: Retina as a window to cerebral dysfunction following studies with circRNA signature during neurodegeneration. *Theranostics* 11: 1814-1827, 2021.
215. Kirk NM, Vieson MD, Selting KA and Reinhart JM: Cytotoxicity of cultured canine primary hepatocytes exposed to itraconazole is decreased by pre-treatment with glutathione. *Front Vet Sci* 8: 621732, 2021.
216. Lan HY, An P, Liu QP, Chen YY, Yu YY, Luan X, Tang JY and Zhang H: Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. *J Ethnopharmacol* 274: 114073, 2021.
217. Li C, Sun G, Chen B, Xu L, Ye Y, He J, Bao Z, Zhao P, Miao Z, Zhao L, *et al*: Nuclear receptor coactivator 4-mediated ferritinophagy contributes to cerebral ischemia-induced ferroptosis in ischemic stroke. *Pharmacol Res* 174: 105933, 2021.
218. Liu X, Xing S, Xu Y, Chen R, Lin C and Guo L: 3-Amino-1,2,4-triazole-derived graphitic carbon nitride for photodynamic therapy. *Spectrochim Acta A Mol Biomol Spectrosc* 250: 119363, 2021.
219. Suo L, Liu C, Zhang QY, Yao MD, Ma Y, Yao J, Jiang Q and Yan B: METTL3-mediated N⁶-methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. *Theranostics* 12: 277-289, 2022.
220. Panel M, Ruiz I, Brillet R, Lafdil F, Teixeira-Clerc F, Nguyen CT, Calderaro J, Gelin M, Allemand F, Guichou JF, *et al*: Small-molecule inhibitors of cyclophilins block opening of the mitochondrial permeability transition pore and protect mice from hepatic ischemia/reperfusion injury. *Gastroenterology* 157: 1368-1382, 2019.
221. Winquist RJ and Gribkoff VK: Targeting putative components of the mitochondrial permeability transition pore for novel therapeutics. *Biochem Pharmacol* 177: 113995, 2020.
222. Yu CH, Davidson S, Harapas CR, Hilton JB, Mlodzianowski MJ, Laohamonthonkul P, Louis C, Low RRJ, Moecking J, De Nardo D, *et al*: TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. *Cell* 183: 636-649.e18, 2020.
223. Wu S and Zou MH: AMPK, mitochondrial function, and cardiovascular disease. *Int J Mol Sci* 21: 4987, 2020.
224. Lee P, Chandel NS and Simon MC: Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. *Nat Rev Mol Cell Biol* 21: 268-283, 2020.
225. Tan KY, Li CY, Li YF, Fei J, Yang B, Fu YJ and Li F: Real-time monitoring ATP in mitochondria of living cells: A specific fluorescent probe for ATP by dual recognition sites. *Anal Chem* 89: 1749-1756, 2017.
226. Arai S, Kriszt R, Harada K, Looi LS, Matsuda S, Wongso D, Suo S, Ishiura S, Tseng YH, Raghunath M, *et al*: RGB-color intensimetric indicators to visualize spatiotemporal dynamics of ATP in single cells. *Angew Chem Int Ed Engl* 57: 10873-10878, 2018.
227. Potter M, Newport E and Morten KJ: The Warburg effect: 80 Years on. *Biochem Soc Trans* 44: 1499-1505, 2016.
228. Nesci S, Pagliarini A, Algieri C and Trombetti F: Mitochondrial F-type ATP synthase: multiple enzyme functions revealed by the membrane-embedded F₀ structure. *Crit Rev Biochem Mol Biol* 55: 309-321, 2020.
229. Schönfeld P and Wojtczak L: Short- and medium-chain fatty acids in energy metabolism: The cellular perspective. *J Lipid Res* 57: 943-954, 2016.
230. Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV and Orekhov AN: The role of mitochondrial dysfunction in cardiovascular disease: A brief review. *Ann Med* 50: 121-127, 2018.
231. Costa R, Peruzzo R, Bachmann M, Montà GD, Vicario M, Santinon G, Mattarei A, Moro E, Quintana-Cabrera R, Scorrano L, *et al*: Impaired mitochondrial ATP production downregulates Wnt signaling via ER stress induction. *Cell Rep* 28: 1949-1960.e6, 2019.
232. Rambold AS and Pearce EL: Mitochondrial dynamics at the interface of immune cell metabolism and function. *Trends Immunol* 39: 6-18, 2018.
233. Roger AJ, Muñoz-Gómez SA and Kamikawa R: The origin and diversification of mitochondria. *Curr Biol* 27: R1177-R1192, 2017.
234. Guntur AR, Gerencser AA, Le PT, DeMambro VE, Bornstein SA, Mookerjee SA, Maridas DE, Clemmons DE, Brand MD and Rosen CJ: Osteoblast-like MC3T3-E1 cells prefer glycolysis for ATP production but adipocyte-like 3T3-L1 cells prefer oxidative phosphorylation. *J Bone Miner Res* 33: 1052-1065, 2018.

235. Depaoli MR, Karsten F, Madreiter-Sokolowski CT, Klec C, Gottschalk B, Bischof H, Eroglu E, Waldeck-Weiermair M, Simmen T, Graier WF and Malli R: Real-time imaging of mitochondrial ATP dynamics reveals the metabolic setting of single cells. *Cell Rep* 25: 501-512.e3, 2018.
236. Hampl V, Čepička I and Eliáš M: Was the mitochondrion necessary to start eukaryogenesis? *Trends Microbiol* 27: 96-104, 2019.
237. Beamer E, Conte G and Engel T: ATP release during seizures—a critical evaluation of the evidence. *Brain Res Bull* 151: 65-73, 2019.
238. Buckel W, Hetzel M and Kim J: ATP-driven electron transfer in enzymatic radical reactions. *Curr Opin Chem Biol* 8: 462-467, 2004.
239. Chen H and Zhang YPJ: Enzymatic regeneration and conservation of ATP: Challenges and opportunities. *Crit Rev Biotechnol* 41: 16-33, 2021.
240. Dorr BM and Fuerst DE: Enzymatic amidation for industrial applications. *Curr Opin Chem Biol* 43: 127-133, 2018.
241. Finley D and Prado MA: The proteasome and its network: Engineering for adaptability. *Cold Spring Harb Perspect Biol* 12: a033985, 2020.
242. Hammler D, Marx A and Zumbusch A: Fluorescence-lifetime-sensitive probes for monitoring ATP cleavage. *Chemistry* 24: 15329-15335, 2018.
243. Ishida A, Yamada Y and Kamidate T: Colorimetric method for enzymatic screening assay of ATP using Fe(III)-xylenol orange complex formation. *Anal Bioanal Chem* 392: 987-994, 2008.
244. Midelfort CF and Rose IA: A stereochemical method for detection of ATP terminal phosphate transfer in enzymatic reactions. *Glutamine synthetase*. *J Biol Chem* 251: 5881-5887, 1976.
245. Ušaj M, Moretto L, Vemula V, Salhotra A and Månsson A: Single molecule turnover of fluorescent ATP by myosin and actomyosin unveil elusive enzymatic mechanisms. *Commun Biol* 4: 64, 2021.
246. Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Hartnett JR, Ingold MR, Zimmerman K, Machleidt T, Kirkland TA, Huwiler KG, *et al*: Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement. *Cell Chem Biol* 25: 206-214.e11, 2018.
247. Klier PEZ, Martin JG and Miller EW: Imaging reversible mitochondrial membrane potential dynamics with a masked rhodamine voltage reporter. *J Am Chem Soc* 143: 4095-4099, 2021.
248. Mita M, Sugawara I, Harada K, Ito M, Takizawa M, Ishida K, Ueda H, Kitaguchi T and Tsuboi T: Development of red genetically encoded biosensor for visualization of intracellular glucose dynamics. *Cell Chem Biol* 29: 98-108.e4, 2022.
249. Murata O, Shindo Y, Ikeda Y, Iwasawa N, Citterio D, Oka K and Hiruta Y: Near-infrared fluorescent probes for imaging of intracellular Mg^{2+} and application to multi-color imaging of Mg^{2+} , ATP, and mitochondrial membrane potential. *Anal Chem* 92: 966-974, 2020.
250. Billingham LK, Stoolman JS, Vasan K, Rodriguez AE, Poor TA, Szibor M, Jacobs HT, Reczek CR, Rashidi A, Zhang P, *et al*: Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. *Nat Immunol* 23: 692-704, 2022.
251. Fernström J, Mellon SH, McGill MA, Picard M, Reus VI, Hough CM, Lin J, Epel ES, McKowitz OM and Lindqvist D: Blood-based mitochondrial respiratory chain function in major depression. *Transl Psychiatry* 11: 593, 2021.
252. Spinelli JB, Rosen PC, Sprenger HG, Puszynska AM, Mann JL, Roessler JM, Cangelosi AL, Henne A, Condon KJ, Zhang T, *et al*: Fumarate is a terminal electron acceptor in the mammalian electron transport chain. *Science* 374: 1227-1237, 2021.
253. Vercellino I and Sazanov LA: The assembly, regulation and function of the mitochondrial respiratory chain. *Nat Rev Mol Cell Biol* 23: 141-161, 2022.
254. Colaço HG, Barros A, Neves-Costa A, Seixas E, Pedrosa D, Velho T, Willmann KL, Faisca P, Grabmann G, Yi HS, *et al*: Tetracycline antibiotics induce host-dependent disease tolerance to infection. *Immunity* 54: 53-67.e7, 2021.
255. Dennerlein S, Wang C and Rehling P: Plasticity of mitochondrial translation. *Trends Cell Biol* 27: 712-721, 2017.
256. Diebold LP, Gil HJ, Gao P, Martinez CA, Weinberg SE and Chandel NS: Mitochondrial complex III is necessary for endothelial cell proliferation during angiogenesis. *Nat Metab* 1: 158-171, 2019.
257. Flønes IH, Ricken G, Klotz S, Lang A, Ströbel T, Dölle C, Kovacs GG and Tzoulis C: Mitochondrial respiratory chain deficiency correlates with the severity of neuropathology in sporadic Creutzfeldt-Jakob disease. *Acta Neuropathol Commun* 8: 50, 2020.
258. Manczak M, Kandimalla R, Yin X and Reddy PH: Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity. *Hum Mol Genet* 28: 177-199, 2019.
259. Markevich NI, Galimova MH and Markevich LN: Hysteresis and bistability in the succinate-CoQ reductase activity and reactive oxygen species production in the mitochondrial respiratory complex II. *Redox Biol* 37: 101630, 2020.
260. Mazat JP, Devin A and Ransac S: Modelling mitochondrial ROS production by the respiratory chain. *Cell Mol Life Sci* 77: 455-465, 2020.
261. Timón-Gómez A, Garlich J, Stuart RA, Ugalde C and Barrientos A: Distinct roles of mitochondrial HIGD1A and HIGD2A in respiratory complex and supercomplex biogenesis. *Cell Rep* 31: 107607, 2020.
262. Grünewald A, Kumar KR and Sue CM: New insights into the complex role of mitochondria in Parkinson's disease. *Prog Neurobiol* 177: 73-93, 2019.
263. Ansó E, Weinberg SE, Diebold LP, Thompson BJ, Malinge S, Schumacker PT, Liu X, Zhang Y, Shao Z, Steadman M, *et al*: The mitochondrial respiratory chain is essential for haematopoietic stem cell function. *Nat Cell Biol* 19: 614-625, 2017.
264. Wang HW, Zhu SQ, Liu J, Miao CY, Zhang Y and Zhou BH: Fluoride-induced renal dysfunction via respiratory chain complex abnormal expression and fusion elevation in mice. *Chemosphere* 238: 124607, 2020.
265. Weiland D, Brachvogel B, Hornig-Do HT, Neuhaus JFG, Holzer T, Tobin DJ, Niessen CM, Wiesner RJ and Baris OR: Imbalance of mitochondrial respiratory chain complexes in the epidermis induces severe skin inflammation. *J Invest Dermatol* 138: 132-140, 2018.
266. Weinberg SE, Singer BD, Steinert EM, Martinez CA, Mehta MM, Martínez-Reyes I, Gao P, Helmin KA, Abdala-Valencia H, Sena LA, *et al*: Mitochondrial complex III is essential for suppressive function of regulatory T cells. *Nature* 565: 495-499, 2019.
267. Wu M, Gu J, Zong S, Guo R, Liu T and Yang M: Research journey of respirasome. *Protein Cell* 11: 318-338, 2020.
268. Yamada S, Ozaki H and Noguchi K: The mitochondrial respiratory chain maintains the photosynthetic electron flow in *Arabidopsis thaliana* leaves under high-light stress. *Plant Cell Physiol* 61: 283-295, 2020.
269. Yamashita K, Miyazaki T, Fukuda Y, Mitsuyama J, Saijo T, Shimamura S, Yamamoto K, Imamura Y, Izumikawa K, Yanagihara K, *et al*: The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes. *Antimicrob Agents Chemother* 63: e00374-19, 2019.
270. Fernandez-Vizarra E and Zeviani M: Mitochondrial disorders of the OXPHOS system. *FEBS Lett* 595: 1062-1106, 2021.
271. Hernansanz-Agustín P, Choya-Foces C, Carregal-Romero S, Ramos E, Oliva T, Villa-Piña T, Moreno L, Izquierdo-Álvarez A, Cabrera-García JD, Cortés A, *et al*: Na^+ controls hypoxic signalling by the mitochondrial respiratory chain. *Nature* 586: 287-291, 2020.
272. Kobayashi A, Azuma K, Ikeda K and Inoue S: Mechanisms underlying the regulation of mitochondrial respiratory chain complexes by nuclear steroid receptors. *Int J Mol Sci* 21: 6683, 2020.
273. Martínez-Reyes I, Cardona LR, Kong H, Vasan K, McElroy GS, Werner M, Kihshen H, Reczek CR, Weinberg SE, Gao P, *et al*: Mitochondrial ubiquinol oxidation is necessary for tumour growth. *Nature* 585: 288-292, 2020.
274. Castellana S, Biagini T, Petrizzelli F, Parca L, Panzironi N, Caputo V, Vescovi AL, Carella M and Mazza T: MitImpact 3: Modeling the residue interaction network of the respiratory chain subunits. *Nucleic Acids Res* 49 (D1): D1282-D1288, 2021.
275. Wang M, Ren X, Wang L, Lu X, Han L, Zhang X and Feng J: A functional analysis of mitochondrial respiratory chain cytochrome bc_1 complex in *Gaeumannomyces tritici* by RNA silencing as a possible target of carabrone. *Mol Plant Pathol* 21: 1529-1544, 2020.
276. Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, Hoff FW, Qiu Y, Hurren R, Gronda M, *et al*: The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. *Sci Transl Med* 12: eaaz8264, 2020.
277. Heyman E, Daussin F, Wieczorek V, Caiazzo R, Matran R, Berthon P, Aucouturier J, Berthoin S, Descatoire A, Leclair E, *et al*: Muscle oxygen supply and use in type 1 diabetes, from ambient air to the mitochondrial respiratory chain: Is there a limiting step? *Diabetes Care* 43: 209-218, 2020.

278. Lobo-Jarne T, Pérez-Pérez R, Fontanesi F, Timón-Gómez A, Wittig I, Peñas A, Serrano-Lorenzo P, García-Consuegra I, Arenas J, Martín MA, *et al*: Multiple pathways coordinate assembly of human mitochondrial complex IV and stabilization of respiratory supercomplexes. *EMBO J* 39: e103912, 2020.
279. Mohanraj K, Wasilewski M, Benincá C, Cysewski D, Poznanski J, Sakowska P, Bugajska Z, Deckers M, Dennerlein S, Fernandez-Vizarra E, *et al*: Inhibition of proteasome rescues a pathogenic variant of respiratory chain assembly factor COA7. *EMBO Mol Med* 11: e9561, 2019.
280. Formosa LE, Dibley MG, Stroud DA and Ryan MT: Building a complex complex: Assembly of mitochondrial respiratory chain complex I. *Semin Cell Dev Biol* 76: 154-162, 2018.
281. Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB and Jiang X: Role of mitochondria in ferroptosis. *Mol Cell* 73: 354-363.e3, 2019.
282. Maclean AE, Hertle AP, Ligas J, Bock R, Balk J and Meyer EH: Absence of complex I is associated with diminished respiratory chain function in european mistletoe. *Curr Biol* 28: 1614-1619.e3, 2018.
283. Senkler J, Rugen N, Eubel H, Hegermann J and Braun HP: Absence of complex I implicates rearrangement of the respiratory chain in European mistletoe. *Curr Biol* 28: 1606-1613.e4, 2018.
284. Signes A and Fernandez-Vizarra E: Assembly of mammalian oxidative phosphorylation complexes I-V and supercomplexes. *Essays Biochem* 62: 255-270, 2018.
285. Kazak L, Chouchani ET, Stavrovskaya IG, Lu GZ, Jedrychowski MP, Egan DF, Kumari M, Kong X, Erickson BK, Szpyt J, *et al*: UCP1 deficiency causes brown fat respiratory chain depletion and sensitizes mitochondria to calcium overload-induced dysfunction. *Proc Natl Acad Sci USA* 114: 7981-7986, 2017.
286. Kozlov AV, Lancaster JR Jr, Meszaros AT and Weidinger A: Mitochondria-mediated pathways of organ failure upon inflammation. *Redox Biol* 13: 170-181, 2017.
287. Letts JA and Sazanov LA: Clarifying the supercomplex: The higher-order organization of the mitochondrial electron transport chain. *Nat Struct Mol Biol* 24: 800-808, 2017.
288. Guo R, Zong S, Wu M, Gu J and Yang M: Architecture of Human Mitochondrial Respiratory Megacomplex I₂III₂IV₂. *Cell* 170: 1247-1257.e12, 2017.
289. Jian C, Xu F, Hou T, Sun T, Li J, Cheng H and Wang X: Deficiency of PHB complex impairs respiratory supercomplex formation and activates mitochondrial flashes. *J Cell Sci* 130: 2620-2630, 2017.
290. Ndi M, Marin-Buena L, Salvatori R, Singh AP and Ott M: Biogenesis of the bc₁ complex of the mitochondrial respiratory chain. *J Mol Biol* 430: 3892-3905, 2018.
291. Priesnitz C and Becker T: Pathways to balance mitochondrial translation and protein import. *Genes Dev* 32: 1285-1296, 2018.
292. Lin KH, Xie A, Rutter JC, Ahn YR, Lloyd-Cowden JM, Nichols AG, Soderquist RS, Koves TR, Muoio DM, MacIver NJ, *et al*: Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity. *Cell Metab* 29: 1217-1231.e7, 2019.
293. Lobo-Jarne T and Ugalde C: Respiratory chain supercomplexes: Structures, function and biogenesis. *Semin Cell Dev Biol* 76: 179-190, 2018.
294. Tsai YL, Coady TH, Lu L, Zheng D, Alland I, Tian B, Shneider NA and Manley JL: ALS/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs. *Genes Dev* 34: 785-805, 2020.
295. Balsa E, Soustek MS, Thomas A, Cogliati S, García-Poyatos C, Martín-García E, Jedrychowski M, Gygi SP, Enriquez JA and Puigserver P: ER and nutrient stress promote assembly of respiratory chain supercomplexes through the PERK-eIF2 α axis. *Mol Cell* 74: 877-890.e6, 2019.
296. Chinopoulos C: Acute sources of mitochondrial NAD⁺ during respiratory chain dysfunction. *Exp Neurol* 327: 113218, 2020.
297. Cogliati S, Lorenzi I, Rigoni G, Caicci F and Soriano ME: Regulation of mitochondrial electron transport chain assembly. *J Mol Biol* 430: 4849-4873, 2018.
298. Nagao T, Shintani Y, Hayashi T, Kioka H, Kato H, Nishida Y, Yamazaki S, Tsukamoto O, Yashirogi S, Yazawa I, *et al*: Higd1a improves respiratory function in the models of mitochondrial disorder. *FASEB J* 34: 1859-1871, 2020.
299. Vankayala R and Hwang KC: Near-infrared-light-activatable nano-material-mediated phototheranostic nanomedicines: An emerging paradigm for cancer treatment. *Adv Mater* 30: e1706320, 2018.
300. Wang S, Zhang Z, Wei S, He F, Li Z, Wang HH, Huang Y and Nie Z: Near-infrared light-controllable MXene hydrogel for tunable on-demand release of therapeutic proteins. *Acta Biomater* 130: 138-148, 2021.
301. Zhang S, Weinberg S, DeBerge M, Gainullina A, Schipma M, Kinchen JM, Ben-Sahra I, Gius DR, Yvan-Charvet L, Chandel NS, *et al*: Efferocytosis fuels requirements of fatty acid oxidation and the electron transport chain to polarize macrophages for tissue repair. *Cell Metab* 29: 443-456.e5, 2019.
302. Luo X, Gong X, Su L, Lin H, Yang Z, Yan X and Gao J: Activatable mitochondria-targeting organoarsenic prodrugs for bioenergetic cancer therapy. *Angew Chem Int Ed Engl* 60: 1403-1410, 2021.
303. Jiang H, Zhang XW, Liao QL, Wu WT, Liu YL and Huang WH: Electrochemical monitoring of paclitaxel-induced ROS release from mitochondria inside single cells. *Small* 15: e1901787, 2019.
304. Kaplan P, Tatarkova Z, Sironova MK, Racay P and Lehotsky J: Homocysteine and mitochondria in cardiovascular and cerebrovascular systems. *Int J Mol Sci* 21: 7698, 2020.
305. Koch RE, Josefson CC and Hill GE: Mitochondrial function, ornamentation, and immunocompetence. *Biol Rev Camb Philos Soc* 92: 1459-1474, 2017.
306. Zhang L, Wang X, Cueto R, Effi C, Zhang Y, Tan H, Qin X, Ji Y, Yang X and Wang H: Biochemical basis and metabolic interplay of redox regulation. *Redox Biol* 26: 101284, 2019.
307. Zhu X, Liu G, Bu Y, Zhang J, Wang L, Tian Y, Yu J, Wu Z and Zhou H: In situ monitoring of mitochondria regulating cell viability by the RNA-specific fluorescent photosensitizer. *Anal Chem* 92: 10815-10821, 2020.
308. Blanco FJ, Valdes AM and Rego-Pérez I: Mitochondrial DNA variation and the pathogenesis of osteoarthritis phenotypes. *Nat Rev Rheumatol* 14: 327-340, 2018.
309. Fuhrmann DC and Brüne B: Mitochondrial composition and function under the control of hypoxia. *Redox Biol* 12: 208-215, 2017.
310. Lee JH and Paull TT: Mitochondria at the crossroads of ATM-mediated stress signaling and regulation of reactive oxygen species. *Redox Biol* 32: 101511, 2020.
311. Madreiter-Sokolowski CT, Thomas C and Ristow M: Interrelation between ROS and Ca²⁺ in aging and age-related diseases. *Redox Biol* 36: 101678, 2020.
312. Angelova PR, Esteras N and Abramov AY: Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention. *Med Res Rev* 41: 770-784, 2021.
313. van der Reest J, Nardini Cecchino G, Haigis MC and Kordowitzki P: Mitochondria: Their relevance during oocyte ageing. *Ageing Res Rev* 70: 101378, 2021.
314. Martins WK, Santos NF, Rocha CS, Bacellar IOL, Tsubone TM, Viotto AC, Matsukuma AY, Abrantes ABP, Siani P, Dias LG and Baptista MS: Parallel damage in mitochondria and lysosomes is an efficient way to photoinduce cell death. *Autophagy* 15: 259-279, 2019.
315. Kleih M, Böppe K, Dong M, Gaißler A, Heine S, Olayioye MA, Aulitzky WE and Essmann F: Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. *Cell Death Dis* 10: 851, 2019.
316. Sidlauskaitė E, Gibson JW, Megson IL, Whitfield PD, Tovmasyan A, Batinic-Haberle I, Murphy MP, Moulton PR and Cobley JN: Mitochondrial ROS cause motor deficits induced by synaptic inactivity: Implications for synapse pruning. *Redox Biol* 16: 344-351, 2018.
317. Yang J, Chen Z, Liu N and Chen Y: Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. *Redox Biol* 19: 158-165, 2018.
318. Erard M, Dupré-Crochet S and Nübe O: Biosensors for spatiotemporal detection of reactive oxygen species in cells and tissues. *Am J Physiol Regul Integr Comp Physiol* 314: R667-R683, 2018.
319. Jiang X, Wang L, Carroll SL, Chen J, Wang MC and Wang J: Challenges and opportunities for small-molecule fluorescent probes in redox biology applications. *Antioxid Redox Signal* 29: 518-540, 2018.
320. Ortega-Villasante C, Burén S, Barón-Sola Á, Martínez F and Hernández LE: In vivo ROS and redox potential fluorescent detection in plants: Present approaches and future perspectives. *Methods* 109: 92-104, 2016.
321. Ortega-Villasante C, Burén S, Blázquez-Castro A, Barón-Sola Á and Hernández LE: Fluorescent in vivo imaging of reactive oxygen species and redox potential in plants. *Free Radic Biol Med* 122: 202-220, 2018.

322. Dragišić Maksimović J, Mojović M, Vučinić Ž and Maksimović V: Spatial distribution of apoplastic antioxidative constituents in maize root. *Physiol Plant* 173: 818-828, 2021.
323. Emoto MC, Sato-Akaba H, Hamaue N, Kawanishi K, Koshino H, Shimohama S and Fujii HG: Early detection of redox imbalance in the APPsw/PS1dE9 mouse model of Alzheimer's disease by in vivo electron paramagnetic resonance imaging. *Free Radic Biol Med* 172: 9-18, 2021.
324. Gotham JP, Li R, Tipple TE, Lancaster JR Jr, Liu T and Li Q: Quantitation of spin probe-detectable oxidants in cells using electron paramagnetic resonance spectroscopy: To probe or to trap? *Free Radic Biol Med* 154: 84-94, 2020.
325. He L, Li MX, Chen F, Yang SS, Ding J, Ding L and Ren NQ: Novel coagulation waste-based Fe-containing carbonaceous catalyst as peroxymonosulfate activator for pollutants degradation: Role of ROS and electron transfer pathway. *J Hazard Mater* 417: 126113, 2021.
326. Hinoshita M, Abe T, Sato A, Maeda Y and Takeyoshi M: Development of a new photosafety test method based on singlet oxygen generation detected using electron spin resonance. *J Appl Toxicol* 41: 247-255, 2021.
327. Matsumoto KI, Ueno M, Shoji Y and Nakanishi I: Heavy-ion beam-induced reactive oxygen species and redox reactions. *Free Radic Res* 55: 450-460, 2021.
328. Mendoza C, Désert A, Khrouz L, Páez CA, Parola S and Heinrichs B: Heterogeneous singlet oxygen generation: In-operando visible light EPR spectroscopy. *Environ Sci Pollut Res Int* 28: 25124-25129, 2021.
329. Okazaki Y, Ishidzu Y, Ito F, Tanaka H, Hori M and Toyokuni S: L-Dehydroascorbate efficiently degrades non-thermal plasma-induced hydrogen peroxide. *Arch Biochem Biophys* 700: 108762, 2021.
330. Prasad A, Manoharan RR, Sedlářová M and Pospíšil P: Free radical-mediated protein radical formation in differentiating monocytes. *Int J Mol Sci* 22: 9963, 2021.
331. Yamaguchi M, Ma T, Tadaki D, Hirano-Iwata A, Watanabe Y, Kanetaka H, Fujimori H, Takemoto E and Niwano M: Bactericidal activity of bulk nanobubbles through active oxygen species generation. *Langmuir*: Aug 2, 2021 (Epub ahead of print).
332. Zhang K, Deng R, Teng X, Li Y, Sun Y, Ren X and Li J: Direct visualization of single-nucleotide variation in mtDNA using a CRISPR/Cas9-mediated proximity ligation assay. *J Am Chem Soc* 140: 11293-11301, 2018.
333. Moriyama M, Koshiba T and Ichinohe T: Influenza A virus M2 protein triggers mitochondrial DNA-mediated antiviral immune responses. *Nat Commun* 10: 4624, 2019.
334. Baumann K: mtDNA robs nuclear dNTPs. *Nat Rev Mol Cell Biol* 20: 663, 2019.
335. Lazo S, Noren Hooten N, Green J, Eitan E, Mode NA, Liu QR, Zonderman AB, Ezike N, Mattson MP, Ghosh P and Evans MK: Mitochondrial DNA in extracellular vesicles declines with age. *Aging Cell* 20: e13283, 2021.
336. Li D, Du X, Guo X, Zhan L, Li X, Yin C, Chen C, Li M, Li B, Yang H and Xing J: Site-specific selection reveals selective constraints and functionality of tumor somatic mtDNA mutations. *J Exp Clin Cancer Res* 36: 168, 2017.
337. Medeiros TC and Graef M: Autophagy determines mtDNA copy number dynamics during starvation. *Autophagy* 15: 178-179, 2019.
338. Fontana GA and Gahlon HL: Mechanisms of replication and repair in mitochondrial DNA deletion formation. *Nucleic Acids Res* 48: 11244-11258, 2020.
339. Wanrooij PH, Tran P, Thompson LJ, Carvalho G, Sharma S, Kreisel K, Navarrete C, Feldberg AL, Watt DL, Nilsson AK, *et al*: Elimination of rNMPs from mitochondrial DNA has no effect on its stability. *Proc Natl Acad Sci USA* 117: 14306-14313, 2020.
340. Wei W and Chinnery PF: Inheritance of mitochondrial DNA in humans: Implications for rare and common diseases. *J Intern Med* 287: 634-644, 2020.
341. Ignatenko O, Chilov D, Paetau I, de Miguel E, Jackson CB, Capin G, Paetau A, Terzioglu M, Euro L and Suomalainen A: Loss of mtDNA activates astrocytes and leads to spongiform encephalopathy. *Nat Commun* 9: 70, 2018.
342. Kasahara T and Kato T: What can mitochondrial DNA analysis tell us about mood disorders? *Biol Psychiatry* 83: 731-738, 2018.
343. Larsson NG and Wedell A: Mitochondria in human disease. *J Intern Med* 287: 589-591, 2020.
344. Bage EK, Fujimori-Tonou N, Kubota-Sakashita M, Kasahara T and Kato T: Unbiased PCR-free spatio-temporal mapping of the mtDNA mutation spectrum reveals brain region-specific responses to replication instability. *BMC Biol* 18: 150, 2020.
345. Chiang JL, Shukla P, Pagidas K, Ahmed NS, Karri S, Gunn DD, Hurd WW and Singh KK: Mitochondria in ovarian aging and reproductive longevity. *Ageing Res Rev* 63: 101168, 2020.
346. Li H, Slone J, Fei L and Huang T: Mitochondrial DNA variants and common diseases: A mathematical model for the diversity of age-related mtDNA mutations. *Cells* 8: 608, 2019.
347. Nissanka N and Moraes CT: Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches. *EMBO Rep* 21: e49612, 2020.
348. West AP and Shadel GS: Mitochondrial DNA in innate immune responses and inflammatory pathology. *Nat Rev Immunol* 17: 363-375, 2017.
349. Asfaram S, Fakhar M, Mohebbali M, Ziaei Hezarjaribi H, Mardani A, Ghezelbash B, Akhoundi B, Zarei Z and Moazeni M: A convenient and sensitive kDNA-PCR for screening of leishmania infantum latent infection among blood donors in a highly endemic focus, northwestern Iran. *Acta Parasitol* 67: 842-850, 2022.
350. Semerikov VL, Semerikova SA, Khrunyk YY and Putintseva YA: Sequence capture of mitochondrial genome with PCR-generated baits provides new insights into the biogeography of the genus *abies* mill. *Plants (Basel)* 11: 762, 2022.
351. Tay E, Chen SC, Green W, Lopez R and Halliday CL: Development of a real-time PCR assay to identify and distinguish between *Cryptococcus neoformans* and *Cryptococcus gattii* species complexes. *J Fungi (Basel)* 8: 462, 2022.
352. Wang J, Balciuniene J, Diaz-Miranda MA, McCormick EM, Aref-Eshghi E, Muir AM, Cao K, Troiani J, Moseley A, Fan Z, *et al*: Advanced approach for comprehensive mtDNA genome testing in mitochondrial disease. *Mol Genet Metab* 135: 93-101, 2022.
353. Yang Z, Slone J and Huang T: Next-generation sequencing to characterize mitochondrial genomic DNA heteroplasmy. *Curr Protoc* 2: e412, 2022.
354. Allouche J, Rachmin I, Adhikari K, Pardo LM, Lee JH, McConnell AM, Kato S, Fan S, Kawakami A, Suita Y, *et al*: NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. *Cell* 184: 4268-4283.e20, 2021.
355. Cornman RS, McKenna JE Jr and Fike JA: Composition and distribution of fish environmental DNA in an adirondack watershed. *PeerJ* 9: e10539, 2021.
356. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abieliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A *et al*: Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)¹. *Autophagy* 17: 1-382, 2021.
357. Matsui H, Ito J, Matsui N, Uechi T, Onodera O and Kakita A: Cytosolic dsDNA of mitochondrial origin induces cytotoxicity and neurodegeneration in cellular and zebrafish models of Parkinson's disease. *Nat Commun* 12: 3101, 2021.
358. Rhie A, McCarthy SA, Fedrigo O, Damas J, Formenti G, Koren S, Uliano-Silva M, Chow W, Fungtammasan A, Kim J, *et al*: Towards complete and error-free genome assemblies of all vertebrate species. *Nature* 592: 737-746, 2021.
359. Rossmann MP, Hoi K, Chan V, Abraham BJ, Yang S, Mullahoo J, Papanastasiou M, Wang Y, Elia I, Perlin JR, *et al*: Cell-specific transcriptional control of mitochondrial metabolism by TIF1γ drives erythropoiesis. *Science* 372: 716-721, 2021.
360. Wiessner M, Maroofian R, Ni MY, Pedroni A, Müller JS, Stucka R, Beetz C, Efthymiou S, Santorelli FM, Alfares AA, *et al*: Biallelic variants in HPDL cause pure and complicated hereditary spastic paraplegia. *Brain* 144: 1422-1434, 2021.
361. Wong HH, Seet SH, Maier M, Gurel A, Traspas RM, Lee C, Zhang S, Talim B, Loh AYT, Chia CY, *et al*: Loss of C2orf69 defines a fatal autoinflammatory syndrome in humans and zebrafish that evokes a glycogen-storage-associated mitochondrialriopathy. *Am J Hum Genet* 108: 1301-1317, 2021.
362. Zhang DG, Zhao T, Hogstrand C, Ye HM, Xu XJ and Luo Z: Oxidized fish oils increased lipid deposition via oxidative stress-mediated mitochondrial dysfunction and the CREB1-Bcl2-Bcln1 pathway in the liver tissues and hepatocytes of yellow catfish. *Food Chem* 360: 129814, 2021.
363. Borsche M, König IR, Delcambre S, Petrucci S, Balck A, Brüggemann N, Zimprich A, Wasner K, Pereira SL, Avenali M, *et al*: Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. *Brain* 143: 3041-3051, 2020.
364. Fernström J, Ohlsson L, Asp M, Lavant E, Holck A, Grudet C, Westrin Å and Lindqvist D: Plasma circulating cell-free mitochondrial DNA in depressive disorders. *PLoS One* 16: e0259591, 2021.

365. Gonçalves VF, Mendes-Silva AP, Koyama E, Vieira E, Kennedy JL and Diniz B: Increased levels of circulating cell-free mtDNA in plasma of late life depression subjects. *J Psychiatr Res* 139: 25-29, 2021.
366. Liu Y, Zhou K, Guo S, Wang Y, Ji X, Yuan Q, Su L, Guo X, Gu X and Xing J: NGS-based accurate and efficient detection of circulating cell-free mitochondrial DNA in cancer patients. *Mol Ther Nucleic Acids* 23: 657-666, 2021.
367. Maresca A, Del Dotto V, Romagnoli M, La Morgia C, Di Vito L, Capristo M, Valentino ML and Carelli V; ER-MITO Study Group: Expanding and validating the biomarkers for mitochondrial diseases. *J Mol Med (Berl)* 98: 1467-1478, 2020.
368. Nie S, Lu J, Wang L and Gao M: Pro-inflammatory role of cell-free mitochondrial DNA in cardiovascular diseases. *IUBMB Life* 72: 1879-1890, 2020.
369. Valenti D, Vacca RA, Moro L and Atlante A: Mitochondria can cross cell boundaries: An overview of the biological relevance, pathophysiological implications and therapeutic perspectives of intercellular mitochondrial transfer. *Int J Mol Sci* 22: 8312, 2021.
370. Zhong XY, Guo Y and Fan Z: Increased level of free-circulating MtDNA in maintenance hemodialysis patients: Possible role in systemic inflammation. *J Clin Lab Anal* 36: e24558, 2022.
371. Zhou G, Li Y, Li S, Liu H, Xu F, Lai X, Zhang Q, Xu J and Wan S: Circulating cell-free mtDNA content as a non-invasive prognostic biomarker in HCC patients receiving TACE and traditional Chinese medicine. *Front Genet* 12: 719451, 2021.
372. Angelova PR, Andruska KM, Midei MG, Barilani M, Atwal P, Tucher O, Milner P, Heerinx F and Shchepinov MS: RT001 in progressive supranuclear palsy-clinical and in-vitro observations. *Antioxidants (Basel)* 10: 1021, 2021.
373. Björklund G, Tinkov AA, Hosnedlová B, Kizek R, Ajsuvakova OP, Chirumbolo S, Skalnaya MG, Peana M, Dadar M, El-Ansary A, *et al*: The role of glutathione redox imbalance in autism spectrum disorder: A review. *Free Radic Biol Med* 160: 149-162, 2020.
374. Blotto BL, Lyra ML, Cardoso MCS, Trefaut Rodrigues M, R Dias I, Marciano-Jr E, Dal Vecchio F, Orrico VGD, Brandão RA, Lopes de Assis C, *et al*: The phylogeny of the casque-headed treefrogs (Hylidae: Hylinae: Lophophyllini). *Cladistics* 37: 36-72, 2021.
375. Langton AK, Ayer J, Griffiths TW, Rashdan E, Naidoo K, Caley MP, Birch-Machin MA, O'Toole EA, Watson REB and Griffiths CEM: Distinctive clinical and histological characteristics of atrophic and hypertrophic facial photoageing. *J Eur Acad Dermatol Venereol* 35: 762-768, 2021.
376. Luo ZL, Sun HY, Wu XB, Cheng L and Ren JD: Epigallocatechin-3-gallate attenuates acute pancreatitis induced lung injury by targeting mitochondrial reactive oxygen species triggered NLRP3 inflammasome activation. *Food Funct* 12: 5658-5667, 2021.
377. Rebelo AP, Eidhof I, Cintra VP, Guillot-Noel L, Pereira CV, Timmann D, Traschütz A, Schöls L, Coarelli G, Durr A, *et al*: Biallelic loss-of-function variations in PRDX3 cause cerebellar ataxia. *Brain* 144: 1467-1481, 2021.
378. Wu HC, Rérolle D, Berthier C, Hleihel R, Sakamoto T, Quentin S, Benhenda S, Morganti C, Wu C, Conte L, *et al*: Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy. *Cancer Discov* 11: 3198-3213, 2021.
379. Feng B, Wang K, Liu J, Mao G, Cui J, Xuan X, Jiang K and Zhang H: Ultrasensitive apurinic/aprimidinic site-specific ratio fluorescent rotor for real-time highly selective evaluation of mtDNA oxidative damage in living cells. *Anal Chem* 91: 13962-13969, 2019.
380. Dabrowski SA, Nikiforov NG, Zhuravlev AD, Orekhov NA, Grechko AV and Orekhov AN: Role of the mtDNA mutations and mitophagy in inflammaging. *Int J Mol Sci* 23: 1323, 2022.
381. Hamel Y, Mauvais FX, Madrange M, Renard P, Lebreton C, Nemazany I, Pellé O, Goudin N, Tang X, Rodero MP, *et al*: Compromised mitochondrial quality control triggers lipid-related rhabdomyolysis. *Cell Rep Med* 2: 100370, 2021.
382. Karshovska E, Wei Y, Subramanian P, Mohibullah R, Geißler C, Baatsch I, Popal A, Corbalán Campos J, Exner N and Schober A: HIF-1α (hypoxia-inducible factor-1α) promotes macrophage necroptosis by regulating miR-210 and miR-383. *Arterioscler Thromb Vasc Biol* 40: 583-596, 2020.
383. Gao F, Li L, Fan J, Cao J, Li Y, Chen L and Peng X: An off-on two-photon carbazole-based fluorescent probe: Highly targeting and super-resolution imaging of mtDNA. *Anal Chem* 91: 3336-3341, 2019.
384. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, *et al*: mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. *EMBO Mol Med* 10: e8262, 2018.
385. Bozi LHM, Campos JC, Zambelli VO, Ferreira ND and Ferreira JCB: Mitochondrially-targeted treatment strategies. *Mol Aspects Med* 71: 100836, 2020.
386. Jing X, Yang F, Shao C, Wei K, Xie M, Shen H and Shu Y: Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Mol Cancer* 18: 157, 2019.
387. Amore G, Romagnoli M, Carbonelli M, Barboni P, Carelli V and La Morgia C: Therapeutic options in hereditary optic neuropathies. *Drugs* 81: 57-86, 2021.
388. Chen JJ and Bhatti MT: Gene therapy for leber hereditary optic neuropathy: Is vision truly RESCUED? *Ophthalmology* 128: 661-662, 2021.
389. Mejia-Vergara AJ, Seleme N, Sadun AA and Karanjia R: Pathophysiology of conversion to symptomatic leber hereditary optic neuropathy and therapeutic implications: A review. *Curr Neurol Neurosci Rep* 20: 11, 2020.
390. Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, Sergott RC, Klopstock T, Sadun AA, Barboni P, *et al*: Efficacy and safety of intravitreal gene therapy for leber hereditary optic neuropathy treated within 6 months of disease onset. *Ophthalmology* 128: 649-660, 2021.
391. Stenton SL, Sheremet NL, Catarino CB, Andreeva NA, Assouline Z, Barboni P, Barel O, Berutti R, Bychkov I, Caporali L, *et al*: Impaired complex I repair causes recessive leber's hereditary optic neuropathy. *J Clin Invest* 131: e138267, 2021.
392. Wang L, Ding H, Chen BT, Fan K, Tian Q, Long M, Liang M, Shi D, Yu C and Qin W: Occult primary white matter impairment in leber hereditary optic neuropathy. *Eur J Neurol* 28: 2871-2881, 2021.
393. Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, Klopstock T, Vignal-Clermont C, Sergott RC, Rudolph G, *et al*: Bilateral visual improvement with unilateral gene therapy injection for leber hereditary optic neuropathy. *Sci Transl Med* 12: eaaz7423, 2020.
394. Heighton JN, Brady LI, Sadikovic B, Bulman DE and Tarnopolsky MA: Genotypes of chronic progressive external ophthalmoplegia in a large adult-onset cohort. *Mitochondrion* 49: 227-231, 2019.
395. Wu Y, Kang L, Wu HL, Hou Y and Wang ZX: Optical coherence tomography findings in chronic progressive external ophthalmoplegia. *Chin Med J (Engl)* 132: 1202-1207, 2019.
396. Del Monte F, Angelini F, Villar AM and Gabbarini F: The arrhythmic risk in Kearns-Sayre syndrome: Still many questions unanswered. *Europace* 23: 980-981, 2021.
397. Di Mambro C, Tamborrino PP and Drago F: The arrhythmic risk in Kearns-Sayre syndrome: Still many questions unanswered-Authors' reply. *Europace* 23: 981-982, 2021.
398. Di Nora C, Paldino A, Miani D, Finato N, Pizzolotto S, De Maglio G, Vendramin I, Sponga S, Nalli C, Sinagra G and Livi U: Heart transplantation in Kearns-Sayre syndrome. *Transplantation* 103: e393-e394, 2019.
399. Nguyen MTB, Micieli J and Margolin E: Teaching neuroImages: Kearns-Sayre syndrome. *Neurology* 92: e519-e520, 2019.
400. Ashton TM, McKenna WG, Kunz-Schughart LA and Higgins GS: Oxidative phosphorylation as an emerging target in cancer therapy. *Clin Cancer Res* 24: 2482-2490, 2018.
401. Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P and Galluzzi L: Targeting mitochondria for cardiovascular disorders: Therapeutic potential and obstacles. *Nat Rev Cardiol* 16: 33-55, 2019.
402. Ni K, Lan G, Veroneau SS, Duan X, Song Y and Lin W: Nanoscale metal-organic frameworks for mitochondria-targeted radiotherapy-radiodynamic therapy. *Nat Commun* 9: 4321, 2018.
403. Porporato PE, Filigheddu N, Pedro JMB, Kroemer G and Galluzzi L: Mitochondrial metabolism and cancer. *Cell Res* 28: 265-280, 2018.
404. Qi T, Chen B, Wang Z, Du H, Liu D, Yin Q, Liu B, Zhang Q and Wang Y: A pH-activatable nanoparticle for dual-stage precisely mitochondria-targeted photodynamic anticancer therapy. *Biomaterials* 213: 119219, 2019.
405. Ramachandra CJA, Hernandez-Resendiz S, Crespo-Avilan GE, Lin YH and Hausenloy DJ: Mitochondria in acute myocardial infarction and cardioprotection. *EBioMedicine* 57: 102884, 2020.
406. Soukas AA, Hao H and Wu L: Metformin as anti-aging therapy: Is it for everyone? *Trends Endocrinol Metab* 30: 745-755, 2019.

407. Bonora E, Chakrabarty S, Kellaris G, Tsutsumi M, Bianco F, Bergamini C, Ullah F, Isidori F, Liparulo I, Diquigiovanni C, *et al*: Biallelic variants in LIG3 cause a novel mitochondrial neurogastrointestinal encephalomyopathy. *Brain* 144: 1451-1466, 2021.
408. D'Angelo R, Boschetti E, Amore G, Costa R, Pugliese A, Caporali L, Gramegna LL, Papa V, Vizioli L, Capristo M, *et al*: Liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Clinical long-term follow-up and pathogenic implications. *J Neurol* 267: 3702-3710, 2020.
409. Hirano M, Carelli V, De Giorgio R, Pironi L, Accarino A, Cenacchi G, D'Alessandro R, Filosto M, Martí R, Nonino F, *et al*: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE international network. *J Inher Metab Dis* 44: 376-387, 2021.
410. Kripps K, Nakayuenyongsuk W, Shayota BJ, Berquist W, Gomez-Ospina N, Esquivel CO, Concepcion W, Sampson JB, Cristin DJ, Jackson WE, *et al*: Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). *Mol Genet Metab* 130: 58-64, 2020.
411. Parés M, Fornaguera C, Vila-Julíà F, Oh S, Fan SHY, Tam YK, Comes N, Vidal F, Martí R, Borrós S and Barquinero J: Preclinical assessment of a gene-editing approach in a mouse model of mitochondrial neurogastrointestinal encephalomyopathy. *Hum Gene Ther* 32: 1210-1223, 2021.
412. Jackson CB, Turnbull DM, Minczuk M and Gammage PA: Therapeutic manipulation of mtDNA heteroplasmy: A shifting perspective. *Trends Mol Med* 26: 698-709, 2020.
413. Jiang Z and Shen H: Mitochondria: Emerging therapeutic strategies for oocyte rescue. *Reprod Sci* 29: 711-722, 2022.
414. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, *et al*: A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. *Nature* 583: 631-637, 2020.
415. Ng YS, Bindoff LA, Gorman GS, Klopstock T, Kornblum C, Mancuso M, McFarland R, Sue CM, Suomalainen A, Taylor RW, *et al*: Mitochondrial disease in adults: Recent advances and future promise. *Lancet Neurol* 20: 573-584, 2021.
416. Fang H, Yao S, Chen Q, Liu C, Cai Y, Geng S, Bai Y, Tian Z, Zacharias AL, Takebe T, *et al*: De novo-designed near-infrared nanoaggregates for super-resolution monitoring of lysosomes in cells, in whole organoids, and in vivo. *ACS Nano* 13: 14426-14436, 2019.
417. Gong X, Pu X, Wang J, Yang L, Cui Y, Li L, Sun X, Liu J, Bai J and Wang Y: Enhancing of nanocatalyst-driven chemodynamic therapy for endometrial cancer cells through inhibition of PINK1/parkin-mediated mitophagy. *Int J Nanomedicine* 16: 6661-6679, 2021.
418. González LF, Bevilacqua LE and Naves R: Nanotechnology-based drug delivery strategies to repair the mitochondrial function in neuroinflammatory and neurodegenerative diseases. *Pharmaceutics* 13: 2055, 2021.
419. Gu X, Kwok RTK, Lam JWY and Tang BZ: AIEgens for biological process monitoring and disease theranostics. *Biomaterials* 146: 115-135, 2017.
420. He C, Jiang S, Yao H, Zhang L, Yang C, Jiang S, Ruan F, Zhan D, Liu G, Lin Z, *et al*: High-content analysis for mitophagy response to nanoparticles: A potential sensitive biomarker for nanosafety assessment. *Nanomedicine* 15: 59-69, 2019.
421. He G, Pan X, Liu X, Zhu Y, Ma Y, Du C, Liu X and Mao C: HIF-1 α -mediated mitophagy determines ZnO nanoparticle-induced human osteosarcoma cell death both in vitro and in vivo. *ACS Appl Mater Interfaces* 12: 48296-48309, 2020.
422. Zhao M, Liu S, Wang C, Wang Y, Wan M, Liu F, Gong M, Yuan Y, Chen Y, Cheng J, *et al*: Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA. *ACS Nano* 15: 1519-1538, 2021.
423. Macdonald R, Barnes K, Hastings C and Mortiboys H: Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: Can mitochondria be targeted therapeutically? *Biochem Soc Trans* 46: 891-909, 2018.
424. Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D and Reiter RJ: Mitochondria and chloroplasts as the original sites of melatonin synthesis: A hypothesis related to melatonin's primary function and evolution in eukaryotes. *J Pineal Res* 54: 127-138, 2013.
425. Lee JH, Park A, Oh KJ, Lee SC, Kim WK and Bae KH: The role of adipose tissue mitochondria: Regulation of mitochondrial function for the treatment of metabolic diseases. *Int J Mol Sci* 20: 4924, 2019.
426. Wallace DC: Mitochondrial genetic medicine. *Nat Genet* 50: 1642-1649, 2018.
427. Strobbe D and Campanella M: Anxiolytic therapy: A paradigm of successful mitochondrial pharmacology. *Trends Pharmacol Sci* 39: 437-439, 2018.
428. Wang XQ, Peng M, Li CX, Zhang Y, Zhang M, Tang Y, Liu MD, Xie BR and Zhang XZ: Real-time imaging of free radicals for mitochondria-targeting hypoxic tumor therapy. *Nano Lett* 18: 6804-6811, 2018.
429. Kim HK, Noh YH, Nilius B, Ko KS, Rhee BD, Kim N and Han J: Current and upcoming mitochondrial targets for cancer therapy. *Semin Cancer Biol* 47: 154-167, 2017.
430. Lleonart ME, Grodzicki R, Graifer DM and Lyakhovich A: Mitochondrial dysfunction and potential anticancer therapy. *Med Res Rev* 37: 1275-1298, 2017.
431. Tian J, Huang B, Cui Z, Wang P, Chen S, Yang G and Zhang W: Mitochondria-targeting and ROS-sensitive smart nanoscale supramolecular organic framework for combinational amplified photodynamic therapy and chemotherapy. *Acta Biomater* 130: 447-459, 2021.
432. Kim HJ, Maiti P and Barrientos A: Mitochondrial ribosomes in cancer. *Semin Cancer Biol* 47: 67-81, 2017.
433. Chen WW, Freinkman E and Sabatini DM: Rapid immunopurification of mitochondria for metabolite profiling and absolute quantification of matrix metabolites. *Nat Protoc* 12: 2215-2231, 2017.
434. Jung HS, Lee JH, Kim K, Koo S, Verwilt P, Sessler JL, Kang C and Kim JS: A mitochondria-targeted cryptocyanine-based photothermogenic photosensitizer. *J Am Chem Soc* 139: 9972-9978, 2017.
435. Roth KG, Mambetsariev I, Kulkarni P and Salgia R: The mitochondrion as an emerging therapeutic target in cancer. *Trends Mol Med* 26: 119-134, 2020.
436. Nash GT, Luo T, Lan G, Ni K, Kaufmann M and Lin W: Nanoscale metal-organic layer isolates phthalocyanines for efficient mitochondria-targeted photodynamic therapy. *J Am Chem Soc* 143: 2194-2199, 2021.
437. Russell OM, Gorman GS, Lightowlers RN and Turnbull DM: Mitochondrial diseases: Hope for the future. *Cell* 181: 168-188, 2020.
438. Saeb-Parsy K, Martin JL, Summers DM, Watson CJE, Krieg T and Murphy MP: Mitochondria as therapeutic targets in transplantation. *Trends Mol Med* 27: 185-198, 2021.
439. Kelly B and Pearce EL: Amino assets: How amino acids support immunity. *Cell Metab* 32: 154-175, 2020.
440. Rahman J and Rahman S: Mitochondrial medicine in the omics era. *Lancet* 391: 2560-2574, 2018.
441. Tabish TA and Narayan RJ: Mitochondria-targeted graphene for advanced cancer therapeutics. *Acta Biomater* 129: 43-56, 2021.
442. Yuan P, Deng FA, Liu YB, Zheng RR, Rao XN, Qiu XZ, Zhang DW, Yu XY, Cheng H and Li SY: Mitochondria targeted O₂ economizer to alleviate tumor hypoxia for enhanced photodynamic therapy. *Adv Healthc Mater* 10: e2100198, 2021.
443. Ballaró R, Lopalco P, Audrito V, Beltrà M, Pin F, Angelini R, Costelli P, Corcelli A, Bonetto A, Szeto HH, *et al*: Targeting mitochondria by SS-31 ameliorates the whole body energy status in cancer- and chemotherapy-induced cachexia. *Cancers (Basel)* 13: 850, 2021.
444. Bhatti JS, Tamarai K, Kandimalla R, Manczak M, Yin X, Ramasubramanian B, Sawant N, Pradeepkiran JA, Vijayan M, Kumar S and Reddy PH: Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho/JngJ mice. *Mitochondrion* 58: 49-58, 2021.
445. Deng HF, Yue LX, Wang NN, Zhou YQ, Zhou W, Liu X, Ni YH, Huang CS, Qiu LZ, Liu H, *et al*: Mitochondrial iron overload-mediated inhibition of Nrf2-HO-1/GPX4 assisted ALI-induced nephrotoxicity. *Front Pharmacol* 11: 624529, 2021.
446. Le Gal K, Wiel C, Ibrahim MX, Henricsson M, Sayin VI and Bergo MO: Mitochondria-targeted antioxidants MitoQ and MitoTEMPO do not influence BRAF-driven malignant melanoma and KRAS-driven lung cancer progression in mice. *Antioxidants (Basel)* 10: 163, 2021.
447. Bhatti JS, Tamarai K, Kandimalla R, Manczak M, Yin X, Kumar S, Vijayan M and Reddy PH: Mitochondria-targeted small peptide, SS31 ameliorates diabetes induced mitochondrial dynamics in male TallyHO/JngJ mice. *Mol Neurobiol* 58: 795-808, 2021.

448. Grosser JA, Fehrman RL, Keefe D, Redmon M and Nickells RW: The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment and activation during apoptosis. *BMC Res Notes* 14: 198, 2021.
449. He Y, Chen Z, Zhang R, Quan Z, Xu Y, He B and Ren Y: Mitochondrial-targeted antioxidant peptide SS31 prevents RPE cell death under oxidative stress. *Biomed Res Int* 2022: 6180349, 2022.
450. He Y, Quan Z, Zhang R, He B, Xu Y, Chen Z, Ren Y and Li K: Preparation of targeted mitochondria nanoscale-release peptides and their efficiency on eukaryotic cells. *J Biomed Nanotechnol* 17: 1679-1689, 2021.
451. He Y, Zhang R, Quan Z, He B, Xu Y, Chen Z, Ren Y and Liu X: Synthesis, characterization, and specific localization of mitochondrial-targeted antioxidant peptide SS31 probe. *Biomed Res Int* 2021: 9915699, 2021.
452. Sun M, Ma J, Ye J, Fan H, Le J and Zhu J: Protective effect of mitochondria-targeted antioxidant peptide SS-31 in sepsis-induced acute kidney injury. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 33: 1418-1422, 2021 (In Chinese).
453. Zhu Y, Luo M, Bai X, Li J, Nie P, Li B and Luo P: SS-31, a mitochondria-targeting peptide, ameliorates kidney disease. *Oxid Med Cell Longev* 2022: 1295509, 2022.
454. Olgar Y, Billur D, Tuncay E and Turan B: MitoTEMPO provides an antiarrhythmic effect in aged-rats through attenuation of mitochondrial reactive oxygen species. *Exp Gerontol* 136: 110961, 2020.
455. Tuncer S, Akkoca A, Celen MC and Dalkilic N: Can MitoTEMPO protect rat sciatic nerve against ischemia-reperfusion injury? *Naunyn Schmiedeberg Arch Pharmacol* 394: 545-553, 2021.
456. Vrijnsen S, Besora-Casals L, van Veen S, Zielich J, Van den Haute C, Hamouda NN, Fischer C, Ghesquière B, Tournev I, Agostinis P, *et al*: ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. *Proc Natl Acad Sci USA* 117: 31198-31207, 2020.
457. Wang Y, Zhao Y, Wang Z, Sun R, Zou B, Li R, Liu D, Lin M, Zhou J, Ning S, *et al*: Peroxiredoxin 3 inhibits acetaminophen-induced liver pyroptosis through the regulation of mitochondrial ROS. *Front Immunol* 12: 652782, 2021.
458. Gao J, Zhan J and Yang Z: Enzyme-instructed self-assembly (EISA) and hydrogelation of peptides. *Adv Mater* 32: e1805798, 2020.
459. Liu C, Liu B, Zhao J, Di Z, Chen D, Gu Z, Li L and Zhao Y: Nd³⁺-sensitized upconversion metal-organic frameworks for mitochondria-targeted amplified photodynamic therapy. *Angew Chem Int Ed Engl* 59: 2634-2638, 2020.
460. Lu M, Qu A, Li S, Sun M, Xu L, Kuang H and Xu C: Mitochondria-targeting plasmonic spiky nanorods increase the elimination of aging cells in vivo. *Angew Chem Int Ed Engl* 59: 8698-8705, 2020.
461. Li C, Zhang W, Liu S, Hu X and Xie Z: Mitochondria-targeting organic nanoparticles for enhanced photodynamic/photothermal therapy. *ACS Appl Mater Interfaces* 12: 30077-30084, 2020.
462. Zhang CX, Cheng Y, Liu DZ, Liu M, Cui H, Zhang BL, Mei QB and Zhou SY: Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. *J Nanobiotechnology* 17: 18, 2019.
463. Sun J, Zhang J, Tian J, Virzì GM, Digvijay K, Cueto L, Yin Y, Rosner MH and Ronco C: Mitochondria in sepsis-induced AKI. *J Am Soc Nephrol* 30: 1151-1161, 2019.
464. Yang G, Chen C, Zhu Y, Liu Z, Xue Y, Zhong S, Wang C, Gao Y and Zhang W: GSH-activatable NIR nanoplatform with mitochondria targeting for enhancing tumor-specific therapy. *ACS Appl Mater Interfaces* 11: 44961-44969, 2019.
465. Gabandé-Rodríguez E, Gómez de Las Heras MM and Mittelbrunn M: Control of inflammation by calorie restriction mimetics: On the crossroad of autophagy and mitochondria. *Cells* 9: 82, 2019.
466. Cho H, Cho YY, Shim MS, Lee JY, Lee HS and Kang HC: Mitochondria-targeted drug delivery in cancers. *Biochim Biophys Acta Mol Basis Dis* 1866: 165808, 2020.
467. Liu K, Zhou Z, Pan M and Zhang L: Stem cell-derived mitochondria transplantation: A promising therapy for mitochondrial encephalomyopathy. *CNS Neurosci Ther* 27: 733-742, 2021.
468. Deng Y, Jia F, Chen X, Jin Q and Ji J: ATP suppression by pH-activated mitochondria-targeted delivery of nitric oxide nanoplatform for drug resistance reversal and metastasis inhibition. *Small* 16: e2001747, 2020.
469. Gao C, Wang Y, Sun J, Han Y, Gong W, Li Y, Feng Y, Wang H, Yang M, Li Z, *et al*: Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer's disease mice. *Acta Biomater* 108: 285-299, 2020.
470. Andrieux P, Chevillard C, Cunha-Neto E and Nunes JPS: Mitochondria as a cellular hub in infection and inflammation. *Int J Mol Sci* 22: 11338, 2021.
471. Zeng WN, Yu QP, Wang D, Liu JL, Yang QJ, Zhou ZK and Zeng YP: Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma. *J Nanobiotechnology* 19: 79, 2021.
472. Nam HY, Hong JA, Choi J, Shin S, Cho SK, Seo J and Lee J: Mitochondria-targeting peptoids. *Bioconjug Chem* 29: 1669-1676, 2018.
473. El-Hattab AW, Zarante AM, Almannai M and Scaglia F: Therapies for mitochondrial diseases and current clinical trials. *Mol Genet Metab* 122: 1-9, 2017.
474. Han Y, Chu X, Cui L, Fu S, Gao C, Li Y and Sun B: Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems. *Drug Deliv* 27: 502-518, 2020.
475. Mohammadinejad R, Moosavi MA, Tavakol S, Vardar DÖ, Hosseini A, Rahmati M, Dini L, Hussain S, Mandegary A and Klionsky DJ: Necrotic, apoptotic and autophagic cell fates triggered by nanoparticles. *Autophagy* 15: 4-33, 2019.
476. Vincent AE, Turnbull DM, Eisner V, Hajnóczky G and Picard M: Mitochondrial nanotunnels. *Trends Cell Biol* 27: 787-799, 2017.
477. Wu T, Liang X, Liu X, Li Y, Wang Y, Kong L and Tang M: Induction of ferroptosis in response to graphene quantum dots through mitochondrial oxidative stress in microglia. *Part Fibre Toxicol* 17: 30, 2020.
478. Wang H, Shi W, Zeng D, Huang Q, Xie J, Wen H, Li J, Yu X, Qin L and Zhou Y: pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer. *J Nanobiotechnology* 19: 152, 2021.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.